var title_f8_13_8400="SGD neutrophil";
var content_f8_13_8400=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F71996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F71996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neutrophil in a patient with neutrophil-specific granule deficiency (SGD)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Leukocytes from a SGD patient showing lack of granules and bilobed nucleus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Robert L Roberts.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_13_8400=[""].join("\n");
var outline_f8_13_8400=null;
var title_f8_13_8401="Pivmecillinam: International drug information";
var content_f8_13_8401=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pivmecillinam: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Maxibol (ES);",
"     </li>",
"     <li>",
"      Melysin (JP);",
"     </li>",
"     <li>",
"      Pivexid (IT);",
"     </li>",
"     <li>",
"      Selecid (ES, PT);",
"     </li>",
"     <li>",
"      Selexid (AT, BE, CH, DK, FI, FR, GB, NO, SE);",
"     </li>",
"     <li>",
"      Tindacilin (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1980078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Amdinocillin;",
"     </li>",
"     <li>",
"      Pivmecillinam Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1980080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Penicillin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1980083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bacterial infections caused by susceptible gram-negative organisms",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1980079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 200-400 mg 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1980082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 200 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10430 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-89768E4622-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_13_8401=[""].join("\n");
var outline_f8_13_8401=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303849\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980078\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980080\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980083\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980079\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821141\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980082\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10430\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10430|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_13_8402="Steroid injection skin hypopigmentation";
var content_f8_13_8402=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F74337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F74337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Skin depigmentation following glucocorticoid injection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 431px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hypopigmentation of the skin caused by a glucocorticoid injection of the elbow is apparent in this image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vaibhav Parekh, MD, MBA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_13_8402=[""].join("\n");
var outline_f8_13_8402=null;
var title_f8_13_8403="Lateral bending of the neck";
var content_f8_13_8403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral bending of the neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 402px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The paravertebral and facet joints of the vertebral bodies and the supporting muscles allow the neck to bend an average of 45 degrees laterally. The patient is asked to relax. The examiner places one hand on the shoulder and one hand on the side of the head. The neck is passively rotated to the affected side and compared to the opposite side. Loss of lateral bending typically accompanies loss of rotation and is a reflection of the degree of cervical arthritis, secondary muscle spasm, or both.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_13_8403=[""].join("\n");
var outline_f8_13_8403=null;
var title_f8_13_8404="Extragenital lichen sclerosus in dark skin";
var content_f8_13_8404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Extragenital lichen sclerosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atrophic plaques with mottled hyperpigmentation are present on the shoulder and arm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_13_8404=[""].join("\n");
var outline_f8_13_8404=null;
var title_f8_13_8405="Hyphema grading table";
var content_f8_13_8405=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Traumatic hyphema: grading and prognosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Brandt MT, Haug RH. Traumatic hyphema: a comprehensive review. J Oral Maxillofac Surg 2001;59:1492.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_13_8405=[""].join("\n");
var outline_f8_13_8405=null;
var title_f8_13_8406="Phendimetrazine: Drug information";
var content_f8_13_8406=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phendimetrazine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/10/3237?source=see_link\">",
"    see \"Phendimetrazine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F208783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bontril&reg; PDM;",
"     </li>",
"     <li>",
"      Bontril&reg; Slow-Release",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bontril&reg;;",
"     </li>",
"     <li>",
"      Plegine&reg;;",
"     </li>",
"     <li>",
"      Statobex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F208795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anorexiant;",
"     </li>",
"     <li>",
"      Sympathomimetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F208785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Appetite suppressant (short-term):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule: 105 mg once daily in the morning before breakfast",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: 17.5-35 mg 2 or 3 times daily, 1 hour before meals (maximum: 70 mg 3 times/day)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F14074738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Appetite suppressant (short-term):",
"     </b>",
"     Oral: Adolescents 17 years: Capsule: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F208786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14049723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied); however, use with caution (renally eliminated).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14049724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F208776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, slow release, oral, as tartrate: 105 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bontril&reg; Slow-Release: 105 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as tartrate: 35 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bontril&reg; PDM: 35 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F208765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F208797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4092458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: Administer 30-60 minutes before morning meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Administer 1 hour before meals",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F208777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term (few weeks) adjunct in exogenous obesity",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Pharmacotherapy for weight loss is recommended only for obese patients with a body mass index &ge;30 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     , or &ge;27 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     in the presence of other risk factors such as hypertension, diabetes, and/or dyslipidemia or a high waist circumference; therapy should be used in conjunction with a comprehensive weight management program.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F208801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bontril PDM&reg; may be confused with Bentyl&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F208793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing, hypertension, ischemic events, palpitation, tachycardia, valvular disease (regurgitant)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, dizziness, headache, insomnia, overstimulation, psychosis, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Changes in libido",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, nausea, stomach pain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria, urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, mydriasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Primary pulmonary hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, tachyphylaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Dilated cardiomyopathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F208779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity or idiosyncrasy to phendimetrazine or other sympathomimetic amines or any component of the formulation; arrhythmias, congestive heart failure, coronary artery disease; pulmonary hypertension; hypertension (uncontrolled); stroke (history of); hyperthyroidism; glaucoma; highly nervous or agitated states, history of drug abuse; use with other anorectic agents or CNS stimulants; during or within 14 days following MAO inhibitor therapy; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F208768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Amphetamines may impair the ability to engage in potentially hazardous activities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Primary pulmonary hypertension (PPH): A rare, frequently fatal disease of the lungs, PPH has been found to occur with increased frequency in patients receiving phendimetrazine. Use of an anorectic agent for &gt;3 months increases the risk of PPH.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Valvular heart disease: The use of some anorexigens has been associated with the development of valvular heart disease. Avoid stimulants in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that could increase the risk of sudden death that these conditions alone carry.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; antidiabetic agent requirements may be altered with anorexigens and concomitant dietary restrictions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution in patients with hypertension and other cardiovascular conditions that might be exacerbated by increases in blood pressure or heart rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tourette's syndrome: Use with caution in patients with Tourette's syndrome; stimulants may unmask tics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anorexigens: Safety and efficacy have not been established for use with other weight loss medications, including over-the-counter or herbal products. Not recommended for use in patients who have used other anorectic agents within the past year.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in this age group due to the risk for causing dependence, hypertension, angina, and myocardial infarction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse potential: Phendimetrazine is pharmacologically related to the amphetamines, which have a high abuse potential; prolonged use may lead to dependency. Prescriptions should be written for the smallest quantity consistent with good patient care to minimize possibility of overdose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Discontinue if satisfactory weight loss has not occurred within the first 4 weeks of treatment, or if tolerance develops. Abrupt discontinuation following prolonged high doses may be associated with extreme fatigue and depression.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F4092448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alkalinizing Agents: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Amphetamines may enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihistamines: Amphetamines may diminish the sedative effect of Antihistamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Amphetamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethosuximide: Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal Acidifying Agents: May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Amphetamines may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Amphetamines may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Amphetamines may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F14049719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Concomitant use may cause adverse drug reaction.  Management: Avoid ethanol.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F208772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4092443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Use is contraindicated during pregnancy. The risks of using appetite-suppressing drugs in pregnant women are not known. Weight loss therapy is generally not recommended for pregnant women. Obese and overweight women should be encouraged to participate in weight reduction programs prior to attempting pregnancy; weight gain during pregnancy should be determined by their prepregnancy BMI and current guidelines.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F208787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14049718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is unknown if phendimetrazine is excreted in breast milk; however, other amphetamines have been detected in breast milk. Due to the potential for adverse reactions in the nursing infant, a decision should be made to discontinue nursing or discontinue the medication, depending on the importance of the drug to the mother. Use of specific products are contraindicated in breast-feeding women. Weight loss therapy is generally not recommended for lactating women. Weight loss programs which include physical activity and nutrition components should be discussed at the 6-week postpartum visit.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F4092457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Most effective when combined with a low calorie diet and behavior modification counseling. Capsule should be taken 30-60 minutes before morning meal; tablet should be taken 1 hour before meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F208780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Phendimetrazine Tartrate ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     105 mg (100): $128.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bontril PDM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     35 mg (100): $72.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Phendimetrazine Tartrate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     35 mg (100): $20.40",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4092460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline cardiac evaluation (for preexisting valvular heart disease, pulmonary hypertension); echocardiogram during therapy; weight, waist circumference; blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F4092452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adult classification of weight by BMI (kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) (NHLBI, 1998):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Underweight: &lt;18.5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Normal: 18.5-24.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Overweight: 25-29.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Obese, class I: 30-34.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Obese, class II: 35-39.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extreme obesity (class III): &ge;40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Waist circumference: In adults with a BMI of 25-34.9 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     , high-risk waist circumference is defined as (NHLBI, 1998):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Men &gt;102 cm (&gt;40 in)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Women &gt;88 cm (&gt;35 in)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F208781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anoran (BE);",
"     </li>",
"     <li>",
"      Antapentan (AT);",
"     </li>",
"     <li>",
"      Atrajine (KP);",
"     </li>",
"     <li>",
"      Fendy 35 (KP);",
"     </li>",
"     <li>",
"      Furing (KP);",
"     </li>",
"     <li>",
"      Obesan-X (ZA);",
"     </li>",
"     <li>",
"      Pendimen (KP);",
"     </li>",
"     <li>",
"      Plegine (IT);",
"     </li>",
"     <li>",
"      Prelu-2 (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F4092450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phendimetrazine is a sympathomimetic amine with pharmacologic properties similar to the amphetamines. The mechanism of action in reducing appetite appears to be secondary to CNS effects, including stimulation of the hypothalamus to release norepinephrine.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4092453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Forms 2 metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Bontril&reg; PDM: ~2 hours; Bontril&reg; Slow Release: ~10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abenhaim L, Moride Y, Brenot F, et al, &ldquo;Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension. International Primary Pulmonary Hypertension Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 335(9):609-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/13/8406/abstract-text/8692238/pubmed\" id=\"8692238\" target=\"_blank\">",
"        8692238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, \"ACOG Committee Opinion Number 315, September 2005. Obesity in Pregnancy,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2005, 106(3):671-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/13/8406/abstract-text/16135613/pubmed\" id=\"16135613\" target=\"_blank\">",
"        16135613",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Dietetic Association; American Society of Nutrition, Siega-Riz AM, et al, \"Position of the American Dietetic Association and American Society for Nutrition: Obesity, Reproduction, and Pregnancy Outcomes,\"",
"      <i>",
"       J Am Diet Assoc",
"      </i>",
"      , 2009, 109(5):918-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/13/8406/abstract-text/19412993/pubmed\" id=\"19412993\" target=\"_blank\">",
"        19412993",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/13/8406/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NHLBI (National Heart, Lung, and Blood Institute) Obesity Education Initiative, &ldquo;Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. The Evidence Report,&rdquo;",
"      <i>",
"       NIH Publication",
"      </i>",
"      No. 98-4083. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, 1998.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine) and NRC (National Research Council), \"Weight Gain During Pregnancy: Reexamining the Guidelines,\" Washington, DC: The National Academies Press, 2009. Available at",
"      <a href=\"file://www.nap.edu\" target=\"_blank\">",
"       file://www.nap.edu",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/13/8406/abstract-text/20669500/pubmed\" id=\"20669500\" target=\"_blank\">",
"        20669500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rostagno C, Caciolli S, Felici M, et al, &ldquo;Dilated Cardiomyopathy Associated With Chronic Consumption of Phendimetrazine,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1996, 131(2):407-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/13/8406/abstract-text/8579044/pubmed\" id=\"8579044\" target=\"_blank\">",
"        8579044",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Snow V, Barry P, Fitterman N, et al, &ldquo;Pharmacologic and Surgical Management of Obesity in Primary Care: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2005, 142(7):525-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/13/8406/abstract-text/15809464/pubmed\" id=\"15809464\" target=\"_blank\">",
"        15809464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;U.S. Preventative Services Task Force. Screening for Obesity in Adults: Recommendations and Rationale,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2003, 139(11):933-49",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/13/8406/abstract-text/14644896/pubmed\" id=\"14644896\" target=\"_blank\">",
"        14644896",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10206 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-F1BE05E961-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_13_8406=[""].join("\n");
var outline_f8_13_8406=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208783\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208784\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208795\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208785\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14074738\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208786\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14049723\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14049724\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208776\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208765\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208797\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092458\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208777\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208801\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208793\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208779\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208768\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299860\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092448\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14049719\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208772\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092443\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208787\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14049718\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092457\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208780\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092460\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092452\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208781\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092450\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092453\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10206\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10206|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/10/3237?source=related_link\">",
"      Phendimetrazine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_13_8407="AP distal radius height";
var content_f8_13_8407=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Distal radius anatomy, antero-posterior (AP) view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 593px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Measurements performed on the AP view include radial inclination, radial height, and ulnar variance. Abnormal measurements are often found in the setting of distal radius fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_13_8407=[""].join("\n");
var outline_f8_13_8407=null;
var title_f8_13_8408="Screening for Chlamydia trachomatis";
var content_f8_13_8408=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for Chlamydia trachomatis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/13/8408/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/13/8408/contributors\">",
"     Byron E Batteiger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/13/8408/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/13/8408/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/13/8408/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/13/8408/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/13/8408/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1790505\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexually transmitted genital infection caused by Chlamydia trachomatis is common, especially among sexually active women and men &lt;25 years of age. Untreated infections are long-lasting and often asymptomatic, but in women can result in pelvic inflammatory disease with its sequelae of infertility and ectopic pregnancy. An estimated 2.8 million new cases occurred in the United States in 2008; only a portion of these, 1.2 million in 2008, are reported [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/1\">",
"     1",
"    </a>",
"    ]. The large number of individuals with undetected infection and the lack of strong protective immunity on reexposure after treatment of existing infection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/2\">",
"     2",
"    </a>",
"    ] sustain ongoing transmission and high prevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to screening for C. trachomatis will be reviewed here. Sexually transmitted C. trachomatis infections in men and women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1790512\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for acquiring C. trachomatis among sexually active persons include [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Youth (adolescents and young adults)",
"     </li>",
"     <li>",
"      History of prior chlamydial infection",
"     </li>",
"     <li>",
"      Multiple sex partners, a recent new sex partner, or a sex partner who has other partners during the last three months",
"     </li>",
"     <li>",
"      Inconsistent or non-use of barrier contraceptives",
"     </li>",
"     <li>",
"      Cervical ectopy",
"     </li>",
"     <li>",
"      History of prior sexually transmitted disease",
"     </li>",
"     <li>",
"      Unmarried status",
"     </li>",
"     <li>",
"      Lower socioeconomic status, or high school education or less",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most important risk factors are young age and prior chlamydial infection. Racial disparities also exist, with age-specific rates of chlamydial infection in the United States markedly higher in African American men and women. Risk factors are considered in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link&amp;anchor=H6#H6\">",
"     \"Genital Chlamydia trachomatis infections in women\", section on 'Risk factors for infection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=see_link&amp;anchor=H7#H7\">",
"     \"Genital Chlamydia trachomatis infections in men\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18432384\">",
"    <span class=\"h1\">",
"     CONSEQUENCES OF GENITAL CHLAMYDIA INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of women with C. trachomatis infection are asymptomatic, clinical manifestations range from cervicitis to pelvic inflammatory disease (PID) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/4\">",
"     4",
"    </a>",
"    ]. Approximately 10 percent of women with chlamydia infection will develop symptomatic PID if left untreated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, many women with tubal factor infertility with no prior history of clinical PID have antibodies consistent with past chlamydial infection, suggesting that chlamydia causes subclinical PID resulting in infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. More limited studies have documented the presence of chlamydia in the upper genital tract of asymptomatic women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\", section on 'Subclinical PID'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PID due to C. trachomatis tends to be associated with higher rates of subsequent infertility than PID caused by N. gonorrhoeae [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/11\">",
"     11",
"    </a>",
"    ]. Untreated chlamydia infection also can increase the risk for premature rupture of the membranes and low birth weight. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link&amp;anchor=H9#H9\">",
"     \"Genital Chlamydia trachomatis infections in women\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    C. trachomatis infection is frequently asymptomatic in men as well as women; the main consequence of asymptomatic infection in men is the risk of transmission to women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=see_link&amp;anchor=H10#H10\">",
"     \"Genital Chlamydia trachomatis infections in men\", section on 'Definition and clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1790519\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC SCREENING TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Highly-sensitive and specific nucleic acid amplification tests (NAATs) have largely replaced other diagnostic tests. Compared to cell culture methods, NAATs have superior sensitivity, similar specificity, and greater ease of sample acquisition and handling [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/12\">",
"     12",
"    </a>",
"    ]. NAATs are also preferred over direct fluorescent antibody tests, enzyme immunoassays, and nucleic acid hybridization tests because of superior sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/12\">",
"     12",
"    </a>",
"    ]. However, nucleic acid amplification techniques are more expensive than other methods, making cost a consideration for large-scale screening programs, particularly in resource-poor countries.",
"   </p>",
"   <p>",
"    Leukocyte esterase testing, which detects the neutrophilic response to chlamydial and other urethral infections in men, is non-specific and is no longer recommended as a screening test.",
"   </p>",
"   <p>",
"    Diagnostic tests for genital chlamydia are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link&amp;anchor=H15#H15\">",
"     \"Genital Chlamydia trachomatis infections in women\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=see_link&amp;anchor=H12#H12\">",
"     \"Genital Chlamydia trachomatis infections in men\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1790526\">",
"    <span class=\"h2\">",
"     Nucleic acid amplification tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nucleic acid amplification tests (NAATs) detect small amounts of chlamydial nucleic acid. Some available NAATs include the ability to detect Neisseria gonorrhoeae from the same specimen. The sensitivities and specificities of NAATs vary somewhat by sample source; however, they are uniformly excellent and superior to other available tests. As an example, in one multicenter trial comparing three NAATs and culture obtained from various sampling sites, the sensitivities and specificities of NAATs performed on self-obtained vaginal swabs were 90.7 to 97.9 percent and 99.0 to 99.6 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NAATs can be performed on a variety of samples that can be collected noninvasively, without the need for pelvic examination in women or for urethral swab sampling in men. NAATs have been validated using urine samples from both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/14\">",
"     14",
"    </a>",
"    ]. NAATs have also proven to be sensitive and specific to detect chlamydial infection at the rectal and oropharyngeal sites among men who have sex with men [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Sensitivities of NAATs at the rectal site range from 95.8 to 100 percent compared to 36.1 to 45.7 percent for culture; specificities for NAATs were 95.6 to 98.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaginal swabs, collected either by the patient or clinician, are the sample type of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/18\">",
"     18",
"    </a>",
"    ] and are preferred over urines due to better sensitivity, comparable specificity, and ease of sample acquisition and handling in the laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/13,19\">",
"     13,19",
"    </a>",
"    ]. In one multicenter study of asymptomatic women aged 15 to 25, for example, the sensitivity of NAAT performed on samples obtained by vaginal swab (either self- or clinician-collected) was 93 percent, compared to 80.6 percent for samples of first catch urine [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/13\">",
"     13",
"    </a>",
"    ]. Self-collected vaginal swabs are well-accepted by women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/20\">",
"     20",
"    </a>",
"    ]. For men, urine samples are easily obtained. Samples can be obtained with no requirement to attend a medical venue. As an example, Internet-based screening strategies based on mail-in home sampling have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Point-of-care testing would be convenient for providing immediate results and the opportunity to initiate treatment when positive. However, there is no test with adequate sensitivity for this purpose, and specificity is not adequate for screening [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/22\">",
"     22",
"    </a>",
"    ]. Liquid-based cytology specimens have proven sensitive and specific for C. trachomatis detection by NAAT and may be suitable for C. trachomatis screening at the time of Pap testing without need to obtain a separate sample [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/23\">",
"     23",
"    </a>",
"    ]. However, it is currently recommended to commence Pap screening at age 21, so this specimen source would not apply to adolescent screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1790533\">",
"    <span class=\"h1\">",
"     PREVENTION AND SCREENING STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians caring for adolescents and young adult women have a unique opportunity and responsibility to prevent chlamydial infection and its consequences. Prevention related to genital chlamydia involves both prevention of the primary infection as well as infection sequelae, and can be categorized as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary prevention &mdash; Preventing C. trachomatis infections before they occur",
"     </li>",
"     <li>",
"      Secondary prevention &mdash; Prompt identification and treatment for symptomatic and asymptomatic chlamydial infections before complications develop",
"     </li>",
"     <li>",
"      Tertiary prevention &mdash; Identifying symptoms suggestive of pelvic inflammatory disease to provide prompt treatment and prevent C. trachomatis-associated infertility and ectopic pregnancy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"       \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41488505\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the Centers for Disease Control and Prevention (CDC) stress education regarding chlamydial infection as an important mode of primary prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/24\">",
"     24",
"    </a>",
"    ]. Behavioral changes to reduce the risk of acquiring and transmitting sexually transmitted infections include delaying the age of first coitus, reducing the number of sexual partners, and using barrier methods of contraception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1790540\">",
"    <span class=\"h2\">",
"     Rationale for screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since most infections in both women and men are asymptomatic, laboratory screening of at risk individuals is a key secondary prevention strategy to identify the majority of infections that would otherwise go undetected.",
"   </p>",
"   <p>",
"    The immediate goal of screening is to identify and treat infected persons before they develop complications (secondary prevention) and to identify, test and treat their sex partners to prevent reinfections. Controlled clinical trials support the use of patient-delivered partner therapy (expedited partner therapy, EPT) for chlamydial infection in heterosexual men and women without testing or examining the partner [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]; however, EPT is allowable in some but not all states in the United States. In women, the primary benefit of screening and treatment is to reduce their personal risk of reproductive sequelae. In men, who have a low risk of sequelae, the main rationale for treatment is to reduce the likelihood of reinfection of their female sex partners. &nbsp;",
"   </p>",
"   <p>",
"    The risks of screening pertain largely to expense of the tests, the infrastructure required to administer them, and the psychological and relationship repercussions of false positive tests which occur infrequently. As an example, the predictive value of a positive test to indicate the presence of disease is 88 percent, assuming a high-risk population (chlamydia prevalence of 8 percent), and a NAAT with a sensitivity of 91 percent and a specificity of 99 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1790547\">",
"    <span class=\"h3\">",
"     Randomized screening trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of screening on reproductive function in women has been studied in only a few prospective controlled trials, evaluating symptomatic pelvic inflammatory disease (PID) as the outcome of interest [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial conducted from 1990 to 1992 involved high-risk women &lt;25 years old who were enrolled in a health maintenance organization [",
"      <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/28\">",
"       28",
"      </a>",
"      ]. Women were randomly assigned either to a group invited to receive a one-time screening test with treatment of those infected, or to receive usual care (control group). The rate of PID after one year of follow-up was",
"      <span class=\"nowrap\">",
"       8/10,000",
"      </span>",
"      woman-months in the intervention group compared to",
"      <span class=\"nowrap\">",
"       18/10,000",
"      </span>",
"      woman-months in the usual care group (RR 0.44, 95% CI 0.20-0.90). The study has been criticized since only 64 percent of the intervention group was actually screened [",
"      <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/29\">",
"       29",
"      </a>",
"      ]. Additionally, concern has been raised that bias may have been introduced by phone contacts to encourage the intervention group to participate. Nevertheless, this is the key study on which existing screening recommendations are based.",
"     </li>",
"     <li>",
"      A group of female and male high school students in Denmark in 1997 were randomly assigned to an intervention group that received home sampling kits for one-time testing and treatment if positive, or to a control group that received usual care [",
"      <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/30\">",
"       30",
"      </a>",
"      ]. Baseline chlamydia testing was performed in 93.4 percent of students in the intervention group and in 7.6 percent in the control group. After one year follow-up, outcomes could be ascertained for 51.1 percent of women in the intervention group and 58.5 percent in the control group. Treatment for PID was reported in significantly fewer women in the intervention group women than in the control group (2.1 versus 4.2 percent). The conclusion was that a single round of screening could reduce the occurrence of PID over the course of the following year.",
"     </li>",
"     <li>",
"      A randomized trial of female college students in London examined rates of PID at one year after a one-time sampling at entry [",
"      <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/5\">",
"       5",
"      </a>",
"      ]. In the intervention group, the sample was analyzed and participants with chlamydial infection were treated. In the control group, the sample was stored and analyzed at the end of the study. Since all of the participants were blinded (except those with positive tests at entry, who were contacted and treated), participants were instructed to be evaluated outside the study if they had symptoms or believed they were at risk. There was no significant difference in the rates of probable or possible PID between the control and intervention groups at one year. However, among those with chlamydia at baseline,",
"      <span class=\"nowrap\">",
"       1/63",
"      </span>",
"      in the intervention group developed PID versus",
"      <span class=\"nowrap\">",
"       7/74",
"      </span>",
"      in the control group (RR 0.17, 95% CI 0.03- 1.01) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/5,31\">",
"       5,31",
"      </a>",
"      ]. Most cases of PID",
"      <span class=\"nowrap\">",
"       (30/38,",
"      </span>",
"      79 percent) occurred in participants with negative baseline chlamydia. Ten of these PID cases were documented to be associated with chlamydia and could not have been prevented by the screening intervention, indicating the importance of ongoing chlamydial transmission and the need for repeated screening over time in at-risk individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data from one controlled trial designed to examine the effect of screening on the prevalence of chlamydia has been published [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/32\">",
"     32",
"    </a>",
"    ]. Women and men ages 16 to 29 years (n = 317,304) listed on municipal registers of three regions of the Netherlands were offered yearly home-based chlamydia screening tests for three years. Participation was relatively low at 16.1, 10.8, and 9.5 percent at first, second, and third invitations, respectively. There was no statistical evidence of reduced chlamydia rates with three rounds of screening, and the population prevalences could not be reliably estimated because of low uptake. Another trial is ongoing in Australia that incorporates multiple rounds of opportunistic screening based in general practices and will evaluate chlamydia prevalence as an end point [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1790554\">",
"    <span class=\"h2\">",
"     Screening guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines on chlamydia screening have been published by the US Preventive Services Task Force (USPSTF) (",
"    <a class=\"graphic graphic_table graphicRef52739 \" href=\"UTD.htm?33/51/34621\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/34,35\">",
"     34,35",
"    </a>",
"    ] and the Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1790561\">",
"    <span class=\"h3\">",
"     Nonpregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 USPSTF recommendation statement advocates screening all sexually active nonpregnant women age 24 years or younger and older nonpregnant women who are at increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/35\">",
"     35",
"    </a>",
"    ]. Increased risk is defined as a history of prior chlamydial or other sexually transmitted infection, new or multiple sex partners, or exchanging sex for drugs or money.",
"   </p>",
"   <p>",
"    CDC guidelines differ slightly in that the upper age limit is 25 years or younger [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, the CDC recommends screening on an annual basis, although the optimal interval for repeat screening is not defined. Because the frequency of new incident infection is highest among those with a prior chlamydial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], CDC also recommends retesting such individuals three months after treatment, regardless of whether partners were treated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The age at which screening should be initiated is not stated in existing guidelines. The time from first intercourse to first chlamydia test is greater for younger sexually active women, compared to older adolescents, in part because providers may not inquire about sexual activity among very young individuals (aged &lt;15 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/38\">",
"     38",
"    </a>",
"    ]. Neither the USPSTF nor CDC recommends screening patients older than 25 years, in the absence of risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1790568\">",
"    <span class=\"h3\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The USPSTF recommends screening for chlamydial infection for all pregnant women aged 24 years or younger, and for older pregnant women with risk factors as defined above, but identifies less supporting evidence for this than for nonpregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/35\">",
"     35",
"    </a>",
"    ]. There are no controlled trials regarding pregnancy outcomes. A case control study [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/39\">",
"     39",
"    </a>",
"    ] and a time series study [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/40\">",
"     40",
"    </a>",
"    ] suggest fewer adverse pregnancy outcomes with successful treatment of chlamydial infection.",
"   </p>",
"   <p>",
"    The CDC recommendations for screening pregnant women are broader than those of the USPSTF in that the CDC recommends screening for all pregnant women, regardless of age. The CDC makes additional recommendations to repeat testing three weeks after completion of therapy to ensure therapeutic cure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/24\">",
"     24",
"    </a>",
"    ]. Both the USPSTF and CDC recommend rescreening during the third trimester to prevent maternal complications and transmission to the neonate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1790575\">",
"    <span class=\"h3\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since adverse outcomes in men are relatively rare, the major rationale for screening is to reduce infection or reinfection of existing partners and transmission to new partners. There are no controlled trials that establish the utility of this strategy.",
"   </p>",
"   <p>",
"    The CDC recommends that selected populations of high-risk men be screened because of high rates of chlamydial infection, if resources exist and if screening men would not materially impact screening in women. These populations include men attending STD clinics; men participating in National Job Training programs; men &lt;30 years of age in the military; men &lt;30 years of age entering jail or juvenile detention; and men whose partners are diagnosed with chlamydia. The CDC also recommends retesting men treated for chlamydia within three months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/24\">",
"     24",
"    </a>",
"    ] because of the high risk of reinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152757\">",
"    <span class=\"h4\">",
"     Men who have sex with men",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC also recommends that sexually active men who have sex with men (MSM) be screened at least annually. More frequent screening at three to six month intervals is suggested for MSM with risk factors (multiple or anonymous sex partners, illicit drug use, or partners who participate in these activities). The rationale for screening is to prevent progression of urethral or rectal infections to symptomatic urethritis, epididymitis or proctitis. (See",
"    <a class=\"local\" href=\"#H1790582\">",
"     'Persons with HIV or increased risk for chlamydia infection'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20120?source=see_link&amp;anchor=H7#H7\">",
"     \"Primary care of gay men\", section on 'HIV'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To evaluate for urethral infection in MSM who engage in insertive anal intercourse, screening should be performed using a NAAT on a urine sample. A rectal swab sample should be used for screening at the rectal site in MSM who engage in receptive anal intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/24\">",
"     24",
"    </a>",
"    ]. Screening for chlamydia is not recommended at the oropharyngeal site because of low prevalence at that site (&lt;2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1790582\">",
"    <span class=\"h3\">",
"     Persons with HIV or increased risk for chlamydia infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC has published guidelines recommending that all persons with HIV infection be screened for chlamydia and other sexually transmitted infections (STIs) on entry into HIV care, and at least annually thereafter if they are sexually active [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/43\">",
"     43",
"    </a>",
"    ]. In addition, more frequent screening (every three to six months) is suggested for asymptomatic individuals at higher risk. Risk factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple or anonymous sex partners",
"     </li>",
"     <li>",
"      Past history of any STI",
"     </li>",
"     <li>",
"      Identification of other behaviors associated with transmission of HIV and other STDs",
"     </li>",
"     <li>",
"      Sex- or needle-sharing partner(s) with any of the above-mentioned risks",
"     </li>",
"     <li>",
"      Developmental changes in life that may lead to behavioral change with increased risky behaviors",
"     </li>",
"     <li>",
"      High prevalence of STDs in the area or in the patient population",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For HIV-infected persons who are men who have sex with men, and who have had receptive anal intercourse, screening of the rectal site is necessary. In one study, 53 percent of chlamydial infections were at nonurethral sites and would be missed by urine NAATs [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/42\">",
"     42",
"    </a>",
"    ]. However, screening of the pharyngeal site is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1790589\">",
"    <span class=\"h2\">",
"     Screening uptake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data provided by commercial and Medicaid health plans to the Healthcare Effectiveness Data and Information Set (HEDIS) for sexually active young female enrollees indicate an increase in rates of screening for genital chlamydial infections, though less than half of eligible women have been screened [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/44\">",
"     44",
"    </a>",
"    ]. In a survey conducted by the Centers for Disease Control in 2006 to 2008, only 38 percent of sexually active young women had been screened in the previous year [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/45\">",
"     45",
"    </a>",
"    ]. In a trial of the effectiveness of a registry in the Netherlands inviting individuals aged 16 to 29 to participate in collecting home-based samples for chlamydia screening, participation was low (16 percent and fell over the three year trial period), with no impact on the overall rate of chlamydia infection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the United States nationally, screening rates increased from 25.3 percent in 2000 to 43.6 percent in 2006, falling slightly to 41.6 percent in 2007. These data reflect rates among individuals with insurance; screening rates are likely lower among those without insurance (18.4 percent of women 16 to 20 year old and 28.2 percent of women 21 to 25 years old) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/44\">",
"     44",
"    </a>",
"    ]. Another study examined longitudinal adherence to screening recommendations of 2,632,365 women aged 15 to 25 years enrolled in 130 commercial insurance plans in the US during 2002 to 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/46\">",
"     46",
"    </a>",
"    ]. Overall, 74.1 percent of women in the target age groups were never tested for chlamydia, and only 0.1 percent of women with five years of enrollment had a test each year as recommended. In addition, chlamydia test rates were lowest in the youngest, higher-risk women.",
"   </p>",
"   <p>",
"    Screening uptake for chlamydia is also problematic in persons with HIV infection. Testing at a Baltimore HIV clinic increased significantly after the CDC guidelines were published [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/43\">",
"     43",
"    </a>",
"    ]. Nonetheless, only 49.1 percent of men who enrolled in the clinic after guideline publication reported that they had ever been tested for gonorrhea or chlamydia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8939081\">",
"    <span class=\"h1\">",
"     TREATMENT FOR POSITIVE SCREENING TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive testing for chlamydia should lead to prompt treatment. Prompt treatment after identification of infection is important, since a few individuals may develop complications in the interval between screening and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific treatment regimens, including recommendations for pregnant women, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34505?source=see_link\">",
"     \"Treatment of Chlamydia trachomatis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Appropriate treatment includes identification and treatment of infected sex partners to prevent re-infection. Where allowed by state law, expedited partner therapy is an appropriate and efficient manner of partner management which can reduce risk of repeat infections in the index patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8408/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1790540\">",
"     'Rationale for screening'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8938954\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most important risk factors for acquiring C trachomatis genital infection among sexually active persons are young age and prior chlamydial infection. The majority of infected men and women are asymptomatic. Pelvic inflammatory disease (PID) develops in approximately 10 percent of women with untreated chlamydia infection. (See",
"      <a class=\"local\" href=\"#H1790512\">",
"       'Risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18432384\">",
"       'Consequences of genital chlamydia infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nucleic acid amplification tests (NAATs) have largely replaced other testing (culture, immunoassays) due to better specificity and sensitivity and ease of performance. NAATs can be done on urine or from vaginal swabs taken without pelvic examination. (See",
"      <a class=\"local\" href=\"#H1790519\">",
"       'Diagnostic screening tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rationale for screening is to prevent chlamydia-related complications in women, primarily pelvic inflammatory disease (PID). Three randomized trials found that screening for chlamydia, and treating positive tests, can decrease rates of PID in young women. We recommend screening all sexually active young women (age &le;25 years) for genital chlamydia infection (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1790554\">",
"       'Screening guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest screening all pregnant women for genital chlamydia, regardless of age, and screening nonpregnant women 25 years and older who are at increased risk for infection (HIV infection, prior chlamydial infection or other sexually transmitted disease, new or multiple sex partners) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1790568\">",
"       'Pregnant women'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1790582\">",
"       'Persons with HIV or increased risk for chlamydia infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest screening men in high-risk populations for chlamydial infection (HIV infection, men attending clinics for sexually transmitted infections, or age &lt;30 in the military or entering jail or detention) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2008.  www.cdc.gov/std/stats08/surv2008-complete.pdf (Accessed on August 13, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/2\">",
"      Batteiger BE, Xu F, Johnson RE, Rekart ML. Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies. J Infect Dis 2010; 201 Suppl 2:S178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/3\">",
"      Datta SD, Sternberg M, Johnson RE, et al. Gonorrhea and chlamydia in the United States among persons 14 to 39 years of age, 1999 to 2002. Ann Intern Med 2007; 147:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/4\">",
"      Cates W Jr, Wasserheit JN. Genital chlamydial infections: epidemiology and reproductive sequelae. Am J Obstet Gynecol 1991; 164:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/5\">",
"      Oakeshott P, Kerry S, Aghaizu A, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ 2010; 340:c1642.",
"     </a>",
"    </li>",
"    <li>",
"     Wiesenfeld, HC, Cates, W, Jr. Sexually Transmitted Diseases and Infertility. In: Sexually Transmitted Diseases, 4, Holmes, KK, Sparling, PF, Stamm, WE, et al (Eds), McGraw Hill, New York  p.1522.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/7\">",
"      Akande VA, Hunt LP, Cahill DJ, et al. Tubal damage in infertile women: prediction using chlamydia serology. Hum Reprod 2003; 18:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/8\">",
"      Meikle SF, Zhang X, Marine WM, et al. Chlamydia trachomatis antibody titers and hysterosalpingography in predicting tubal disease in infertility patients. Fertil Steril 1994; 62:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/9\">",
"      Keilani A, Boulieu D, Raudrant D, et al. [Role of Chlamydia trachomatis in tubal pathology (acute salpingitis and tubal sterility). Microbiological study of 175 samples of peritoneal fluid]. J Gynecol Obstet Biol Reprod (Paris) 1989; 18:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/10\">",
"      Shepard MK, Jones RB. Recovery of Chlamydia trachomatis from endometrial and fallopian tube biopsies in women with infertility of tubal origin. Fertil Steril 1989; 52:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/11\">",
"      Tubal infertility: serologic relationship to past chlamydial and gonococcal infection. World Health Organization Task Force on the Prevention and Management of Infertility. Sex Transm Dis 1995; 22:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/12\">",
"      Johnson RE, Newhall WJ, Papp JR, et al. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections--2002. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/13\">",
"      Schachter J, McCormack WM, Chernesky MA, et al. Vaginal swabs are appropriate specimens for diagnosis of genital tract infection with Chlamydia trachomatis. J Clin Microbiol 2003; 41:3784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/14\">",
"      Cook RL, Hutchison SL, &Oslash;stergaard L, et al. Systematic review: noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med 2005; 142:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/15\">",
"      Schachter J, Moncada J, Liska S, et al. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis 2008; 35:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/16\">",
"      Mimiaga MJ, Mayer KH, Reisner SL, et al. Asymptomatic gonorrhea and chlamydial infections detected by nucleic acid amplification tests among Boston area men who have sex with men. Sex Transm Dis 2008; 35:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/17\">",
"      Bachmann LH, Johnson RE, Cheng H, et al. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. J Clin Microbiol 2010; 48:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/18\">",
"      Schachter J, Chernesky MA, Willis DE, et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections. Sex Transm Dis 2005; 32:725.",
"     </a>",
"    </li>",
"    <li>",
"     Association of Public Health Laboratories and Centers for Disease Control and Prevention. Laboratory diagnostic testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Expert Consultation Meeting Summary Report, January 13-15, 2009, Atlanta, GA.  www.aphl.org/aphlprograms/infectious/std/Documents/CTGCLabGuidelinesMeetingReport .pdf (Accessed on August 19, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/20\">",
"      Chernesky MA, Hook EW 3rd, Martin DH, et al. Women find it easy and prefer to collect their own vaginal swabs to diagnose Chlamydia trachomatis or Neisseria gonorrhoeae infections. Sex Transm Dis 2005; 32:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/21\">",
"      Gaydos CA, Dwyer K, Barnes M, et al. Internet-based screening for Chlamydia trachomatis to reach non-clinic populations with mailed self-administered vaginal swabs. Sex Transm Dis 2006; 33:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/22\">",
"      Hislop J, Quayyum Z, Flett G, et al. Systematic review of the clinical effectiveness and cost-effectiveness of rapid point-of-care tests for the detection of genital chlamydia infection in women and men. Health Technol Assess 2010; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/23\">",
"      Chernesky M, Freund GG, Hook E 3rd, et al. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae infections in North American women by testing SurePath liquid-based Pap specimens in APTIMA assays. J Clin Microbiol 2007; 45:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/24\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/25\">",
"      Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005; 352:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/26\">",
"      Schillinger JA, Kissinger P, Calvet H, et al. Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial. Sex Transm Dis 2003; 30:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/27\">",
"      Low N, Bender N, Nartey L, et al. Effectiveness of chlamydia screening: systematic review. Int J Epidemiol 2009; 38:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/28\">",
"      Scholes D, Stergachis A, Heidrich FE, et al. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996; 334:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/29\">",
"      Sellors J, Paavonen J. Screening for chlamydia to prevent pelvic inflammatory disease. N Engl J Med 1996; 335:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/30\">",
"      Ostergaard L, Andersen B, M&oslash;ller JK, Olesen F. Home sampling versus conventional swab sampling for screening of Chlamydia trachomatis in women: a cluster-randomized 1-year follow-up study. Clin Infect Dis 2000; 31:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/31\">",
"      Low N, Hocking J. The POPI trial: what does it mean for chlamydia control now? Sex Transm Infect 2010; 86:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/32\">",
"      van den Broek IV, van Bergen JE, Brouwers EE, et al. Effectiveness of yearly, register based screening for chlamydia in the Netherlands: controlled trial with randomised stepped wedge implementation. BMJ 2012; 345:e4316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/33\">",
"      Hocking JS, Spark S, Guy R, et al. The Australian chlamydia control effectiveness pilot (ACCEPt): first results from a randomised trial of annual chlamydia screening in general practice. Sex Transm Infect 2012; 88:Suppl 1 A3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/34\">",
"      Meyers DS, Halvorson H, Luckhaupt S, U.S. Preventive Services Task Force. Screening for chlamydial infection: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 2007; 147:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/35\">",
"      U.S. Preventive Services Task Force. Screening for chlamydial infection: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2007; 147:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/36\">",
"      Hosenfeld CB, Workowski KA, Berman S, et al. Repeat infection with Chlamydia and gonorrhea among females: a systematic review of the literature. Sex Transm Dis 2009; 36:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/37\">",
"      Batteiger BE, Tu W, Ofner S, et al. Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis 2010; 201:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/38\">",
"      Tu W, Batteiger BE, Wiehe S, et al. Time from first intercourse to first sexually transmitted infection diagnosis among adolescent women. Arch Pediatr Adolesc Med 2009; 163:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/39\">",
"      Ryan GM Jr, Abdella TN, McNeeley SG, et al. Chlamydia trachomatis infection in pregnancy and effect of treatment on outcome. Am J Obstet Gynecol 1990; 162:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/40\">",
"      Cohen I, Veille JC, Calkins BM. Improved pregnancy outcome following successful treatment of chlamydial infection. JAMA 1990; 263:3160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/41\">",
"      Fung M, Scott KC, Kent CK, Klausner JD. Chlamydial and gonococcal reinfection among men: a systematic review of data to evaluate the need for retesting. Sex Transm Infect 2007; 83:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/42\">",
"      Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis 2005; 41:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/43\">",
"      Centers for Disease Control and Prevention (CDC), Health Resources and Services Administration, National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. Incorporating HIV prevention into the medical care of persons living with HIV. Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/44\">",
"      Centers for Disease Control and Prevention (CDC). Chlamydia screening among sexually active young female enrollees of health plans--United States, 2000-2007. MMWR Morb Mortal Wkly Rep 2009; 58:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/45\">",
"      Mitka M. CDC: improve targeted screening for chlamydia. JAMA 2012; 307:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/46\">",
"      Heijne JC, Tao G, Kent CK, Low N. Uptake of regular chlamydia testing by U.S. women: a longitudinal study. Am J Prev Med 2010; 39:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/47\">",
"      Berry SA, Ghanem KG, Page KR, et al. Gonorrhoea and chlamydia testing rates of HIV-infected men: low despite guidelines. Sex Transm Infect 2010; 86:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8408/abstract/48\">",
"      Geisler WM, Wang C, Morrison SG, et al. The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment. Sex Transm Dis 2008; 35:119.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7601 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-69ABC6F150-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_13_8408=[""].join("\n");
var outline_f8_13_8408=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8938954\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1790505\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1790512\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18432384\">",
"      CONSEQUENCES OF GENITAL CHLAMYDIA INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1790519\">",
"      DIAGNOSTIC SCREENING TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1790526\">",
"      Nucleic acid amplification tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1790533\">",
"      PREVENTION AND SCREENING STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41488505\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1790540\">",
"      Rationale for screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1790547\">",
"      - Randomized screening trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1790554\">",
"      Screening guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1790561\">",
"      - Nonpregnant women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1790568\">",
"      - Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1790575\">",
"      - Men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H152757\">",
"      Men who have sex with men",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1790582\">",
"      - Persons with HIV or increased risk for chlamydia infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1790589\">",
"      Screening uptake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8939081\">",
"      TREATMENT FOR POSITIVE SCREENING TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8938954\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/7601\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7601|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/51/34621\" title=\"table 1\">",
"      USPSTF Chlamydia screening recommendations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20120?source=related_link\">",
"      Primary care of gay men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34505?source=related_link\">",
"      Treatment of Chlamydia trachomatis infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_13_8409="Epidemiology, diagnosis, and management of trachoma";
var content_f8_13_8409=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, diagnosis, and management of trachoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/13/8409/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/13/8409/contributors\">",
"     Heathcote R Wright, MBBS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/13/8409/contributors\">",
"     Hugh R Taylor, AC, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/13/8409/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/13/8409/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/13/8409/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/13/8409/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/13/8409/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trachoma is a contagious eye infection caused by Chlamydia trachomatis and is the leading infectious cause of blindness worldwide. C. trachomatis is transmitted by intimate social or sexual contact. Serotypes A, B, Ba and C cause trachoma, and serotypes D-K cause genital tract infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trachoma is endemic in over 50 countries [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/1\">",
"     1",
"    </a>",
"    ]. It is generally confined to poor populations in developing nations of Africa, the Middle East, Asia, Latin America, Pacific Islands, and remote Aboriginal communities in Australia (",
"    <a class=\"graphic graphic_figure graphicRef70030 \" href=\"UTD.htm?18/50/19238\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Worldwide, over 80 million people have active trachoma, over 7 million have trichiasis (ingrown eyelashes), and over 1 million have blindness due to corneal scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Active infection with C. trachomatis is mostly seen in young children with a peak incidence around four to six years, while subsequent scarring and blindness is seen in adults (",
"    <a class=\"graphic graphic_figure graphicRef78281 \" href=\"UTD.htm?16/57/17310\">",
"     figure 2",
"    </a>",
"    ). In many regions, women have two to six times the rate of trachoma than men [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], which may be due to women's continued exposure to children with C. trachomatis infection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trachoma is spread by direct contact with eye, nose, and throat secretions from affected individuals (",
"    <a class=\"graphic graphic_figure graphicRef63925 \" href=\"UTD.htm?28/19/28990\">",
"     figure 3",
"    </a>",
"    ). It can also be spread by contact with fomites such as handkerchiefs, towels, or washcloths contaminated with these secretions. Eye-seeking flies such as Musca sorbens can carry C. trachomatis, but there is no animal or insect reservoir [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/2,8,9\">",
"     2,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In endemic areas, the diagnosis of trachoma is made on the basis of the clinical manifestations of the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The findings are then used to categorize the severity of disease using the Simplified WHO Trachoma Grading System (",
"    <a class=\"graphic graphic_table graphicRef54009 \" href=\"UTD.htm?11/15/11515\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Alternative causes of conjunctivitis should also be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=see_link\">",
"     \"Conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of trachoma can be divided into two phases: active trachoma and cicatricial disease. Active trachoma is mostly seen in young children, whereas cicatricial disease and blindness is seen in adults (",
"    <a class=\"graphic graphic_figure graphicRef78281 \" href=\"UTD.htm?16/57/17310\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Active trachoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial isolated infection with C. trachomatis causes a mild, self-limited follicular conjunctivitis (",
"    <a class=\"graphic graphic_figure graphicRef54272 \" href=\"UTD.htm?1/41/1681\">",
"     figure 4",
"    </a>",
"    ). Although some individuals with active trachoma have a mucopurulent discharge, the majority of cases are relatively asymptomatic, and a screening program is generally required to establish the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Survey assessment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The major physical finding of active trachoma is the characteristic follicle on the superior tarsal conjunctiva. The follicles are large white or pale yellow foci of inflammatory material with a diameter of 0.5 to 2 mm, as in Panel A (",
"    <a class=\"graphic graphic_picture graphicRef73800 \" href=\"UTD.htm?26/57/27540\">",
"     picture 1",
"    </a>",
"    ). An individual with five or more follicles should be categorized as WHO grade TF or TI depending on the severity of inflammation (",
"    <a class=\"graphic graphic_table graphicRef54009 \" href=\"UTD.htm?11/15/11515\">",
"     table 1",
"    </a>",
"    ). Papillae may appear alongside the follicles as pinpoint red dots, but can become much larger and can coalesce to give the conjunctiva a thickened and edematous appearance, as in Panel B (",
"    <a class=\"graphic graphic_picture graphicRef81505 \" href=\"UTD.htm?7/32/7686\">",
"     picture 2",
"    </a>",
"    ). In later disease, the follicles leave grossly visible shallow pits in the cornea (Herbert's pits) that are pathognomonic for trachoma, as in Panel B (",
"    <a class=\"graphic graphic_picture graphicRef73800 \" href=\"UTD.htm?26/57/27540\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These findings of active trachoma are largely observed in children. Older individuals with C. trachomatis infection often do not display a follicular response but may develop a papillary reaction, particularly if there is secondary bacterial infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Cicatricial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity and duration of active trachoma infection predicts the likelihood of progression to cicatricial disease in adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Repeated episodes of infection cause marked conjunctival inflammation, leading to eyelid scarring, as in Panel A (",
"    <a class=\"graphic graphic_picture graphicRef54671 \" href=\"UTD.htm?2/52/2885\">",
"     picture 3",
"    </a>",
"    ). A thick band near the lid margin (Arlt's line) may also be seen, as in Panel B (",
"    <a class=\"graphic graphic_picture graphicRef54671 \" href=\"UTD.htm?2/52/2885\">",
"     picture 3",
"    </a>",
"    ). These findings correspond with WHO grade TS (",
"    <a class=\"graphic graphic_table graphicRef54009 \" href=\"UTD.htm?11/15/11515\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Eyelid scar tissue eventually contracts and can distort the lid margin leading to entropion (inward rolling of the eyelid) and subsequent trichiasis (ingrown eyelashes), as in Panel A (",
"    <a class=\"graphic graphic_picture graphicRef62649 \" href=\"UTD.htm?26/26/27046\">",
"     picture 4",
"    </a>",
"    ). These findings correlate with WHO grade TT (",
"    <a class=\"graphic graphic_table graphicRef54009 \" href=\"UTD.htm?11/15/11515\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Individuals with trichiasis have a greatly increased risk of blindness and for this reason trichiasis is staged as minor (one to five eyelashes touching the globe) or major (more than five eyelashes touching the globe). The finding of trichiasis should prompt surgical intervention (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Treatment and elimination'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Eyelash abrasion on the cornea leads to corneal edema, ulceration and scarring. If untreated, corneal pannus (inflammatory vascular tissue) eventually develops, as in Panel B (",
"    <a class=\"graphic graphic_picture graphicRef62649 \" href=\"UTD.htm?26/26/27046\">",
"     picture 4",
"    </a>",
"    ), followed by corneal opacification, as in Panel C (",
"    <a class=\"graphic graphic_picture graphicRef62649 \" href=\"UTD.htm?26/26/27046\">",
"     picture 4",
"    </a>",
"    ), and loss of vision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Grading",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations are used to categorize the severity of infection in the Simplified WHO Trachoma Grading System (",
"    <a class=\"graphic graphic_table graphicRef54009 \" href=\"UTD.htm?11/15/11515\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To grade the severity of infection, each eye should be examined with at least 2.5x magnification and a good light (",
"    <a class=\"graphic graphic_figure graphicRef54272 \" href=\"UTD.htm?1/41/1681\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef81505 \" href=\"UTD.htm?7/32/7686\">",
"     picture 2",
"    </a>",
"    ). The conjunctiva should be evaluated for inflammation or discharge, and it should be noted whether eyelashes rub against the cornea and whether eyelashes have been removed. The cornea should be examined for evidence of inflammation or opacification, and the upper lid should be everted to visualize the upper tarsal conjunctiva for evidence of follicles, inflammation or scarring.",
"   </p>",
"   <p>",
"    The Simplified WHO Trachoma Grading System is summarized below and in the table (",
"    <a class=\"graphic graphic_table graphicRef54009 \" href=\"UTD.htm?11/15/11515\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trachomatous inflammation, follicular (TF) &mdash; Five or more follicles of &gt;0.5 mm on the upper tarsal conjunctiva, as in Panel A (",
"      <a class=\"graphic graphic_picture graphicRef73800 \" href=\"UTD.htm?26/57/27540\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Trachomatous inflammation, intense (TI) &mdash; Papillary hypertrophy and inflammatory thickening of the upper tarsal conjunctiva obscuring more than half the deep tarsal vessels (",
"      <a class=\"graphic graphic_picture graphicRef81505 \" href=\"UTD.htm?7/32/7686\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Trachomatous conjunctival scarring (TS) &mdash; Grossly visible scars on the tarsal conjunctiva, as in Panel A (",
"      <a class=\"graphic graphic_picture graphicRef54671 \" href=\"UTD.htm?2/52/2885\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Trachomatous trichiasis (TT) &mdash; At least one ingrown eyelash touching the globe, or evidence of epilation (eyelash removal), as in Panel A (",
"      <a class=\"graphic graphic_picture graphicRef62649 \" href=\"UTD.htm?26/26/27046\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Corneal opacity (CO) &mdash; Corneal opacity blurring part of the pupil margin, as in Panel C (",
"      <a class=\"graphic graphic_picture graphicRef62649 \" href=\"UTD.htm?26/26/27046\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The signs in the WHO Trachoma Grading System are useful for decisions regarding intervention. The prevalence of active trachoma (TF or TI) in children aged one to nine is the key index for determining whether an area needs mass antibiotic treatment and hygienic interventions. The prevalence of trichiasis (TT) determines the probable need for surgical services. The prevalence of corneal opacity (CO) is a rough measure of the burden of visual impairment due to trachoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most endemic areas the diagnosis of trachoma is made clinically. However, laboratory assays are available for the diagnosis of C. trachomatis infection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/17\">",
"     17",
"    </a>",
"    ]. Tests include immunofluorescent cytology, PCR, Giemsa cytology, and culture. Although these are useful in research studies or for diagnosis in areas with low prevalence, most trachoma control programs rely on the clinical grading scheme [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. As the positive predictive value of clinical diagnosis for trachoma falls with decreasing prevalence, microbiologic diagnosis may become a more important tool [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/18,20\">",
"     18,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SURVEY ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since most patients with active trachoma are asymptomatic and are young children (",
"    <a class=\"graphic graphic_figure graphicRef78281 \" href=\"UTD.htm?16/57/17310\">",
"     figure 2",
"    </a>",
"    ), survey methods are needed to identify populations at risk. The choice of a survey method must take into account the anticipated trachoma prevalence and concerns specific to a local community. Population-based surveys remain the gold standard for determining prevalence and for establishing and monitoring intervention programs. Rapid assessment protocols also have an important role.",
"   </p>",
"   <p>",
"    In population-based surveys, children aged one to nine years in regions at risk are surveyed to determine the prevalence of active trachoma (TF), and adults over 40 are surveyed to determine the prevalence of trachomatous trichiasis (TT) and cicatricial disease. The resulting prevalence data can be used to determine whether a control program is needed. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Treatment and elimination'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, population-based surveys have several limitations. Without a large sample size, this method may fail to detect a low prevalence of disease. Surveys are also expensive, time consuming, and may divert resources and attention from other important health issues in the community. For these reasons, rapid assessment protocols have been devised for more efficient trachoma screening:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trachoma rapid assessment (TRA) uses known socioeconomic conditions to select the highest risk areas of a region for initial screening [",
"      <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. The information can then be used to determine to prioritize where further surveys and treatment are needed, although it does not provide a prevalence estimate.",
"     </li>",
"     <li>",
"      Acceptance Sampling Trachoma Rapid Assessment (ASTRA) screens children until a predetermined number with active disease are identified, at which point screening is ceased and work can commence on implementation of treatment programs [",
"      <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Such surveys can be completed rapidly to facilitate early implementation of treatment programs when needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    According to World Health Organization (WHO) guidelines, all members of a community should receive mass antibiotic treatment when the prevalence of active trachoma is greater than 10 percent among one to nine year-old children (",
"    <a class=\"graphic graphic_figure graphicRef78281 \" href=\"UTD.htm?16/57/17310\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT AND ELIMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an international commitment led by WHO to eliminate blinding trachoma from the world by 2020, known as the Alliance for the Global Elimination of Trachoma by 2020 (GET 2020).",
"   </p>",
"   <p>",
"    The SAFE strategy (Surgery, Antibiotics, Facial cleanliness and Environmental improvement) is the core tool of GET 2020 and has been proven effective in reducing the incidence of blindness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/26\">",
"     26",
"    </a>",
"    ]. Because blindness due to trachoma is irreversible, the strategy focuses on prevention. Surgical correction of trichiasis prevents the development of corneal opacification, while antibiotics, facial cleanliness, and environmental improvements may disrupt the cycle of reinfection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Mass treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because C. trachomatis is highly infectious and transmitted rapidly in areas of poor hygiene, trachoma is best managed within an entire region rather than on an individual basis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/18,25,27-33\">",
"     18,25,27-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    WHO guidelines recommend that a region should receive mass antibiotic treatment when the prevalence of active trachoma among one- to nine-year-old children (as assessed clinically) is greater than 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/25\">",
"     25",
"    </a>",
"    ]. Subsequent annual treatment should be administered for three years, at which time the prevalence should be reassessed. Annual treatment should continue until the prevalence drops below 5 percent. If the prevalence among one to nine year-old children is less than 10 percent, antibiotic treatment should be administered to households of individuals with active trachoma.",
"   </p>",
"   <p>",
"    However, it is uncertain whether the WHO strategy described above is always appropriate; one or two treatments may be sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], and decline in the prevalence of clinical trachoma can lag behind the fall in the prevalence of infection detected by PCR testing of conjunctival swabs [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/20\">",
"     20",
"    </a>",
"    ]. RNA-based testing may be more sensitive for detection of ocular chlamydia than DNA-based testing, although the clinical significance of this is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In areas where the prevalence is greater than 50 percent, repeated mass antibiotic distribution may be a viable tool for trachoma elimination [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. This was illustrated in a study of three Ethiopian villages including 710 patients who received biannual mass oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    distribution; over a 30-month period, the mean prevalence declined from 43 to &lt;1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, a randomized trial of annual versus biannual mass treatment among over 14,000 individuals demonstrated that biannual distribution leads to a lower trachoma prevalence than annual distribution (6.8 versus 0.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/40\">",
"     40",
"    </a>",
"    ]. However, routine biannual antibiotic distribution in endemic areas is not yet part of the WHO guidelines.",
"   </p>",
"   <p>",
"    Frequent mass antibiotic treatment of children may confer &ldquo;herd protection&rdquo; to the entire community. This was illustrated in a cluster randomized trial including over 10,000 children in Ethiopia in which children ages 1 to 10 years in designated geographic regions were randomized to receive single dose oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    four times per year or to delayed treatment after the study [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/41\">",
"     41",
"    </a>",
"    ]. After 12 months, the mean prevalence of infection among treated children &le;10 years decreased (48 to 3 percent); among individuals &gt;10 years in the communities where children received treatment, the mean prevalence was reduced 47 percent from baseline and was 35 percent lower than in the untreated communities.",
"   </p>",
"   <p>",
"    Mass antibiotic treatment for trachoma may have additional benefits unrelated to trachoma, including the reduction in childhood mortality (due to other infections, including respiratory infections, diarrhea, and malaria). This was illustrated in a cohort including 5507 children in Ethiopia aged one to five years of age who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    for mass treatment of trachoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/42\">",
"     42",
"    </a>",
"    ]. All-cause mortality and infectious mortality were both lower among those who received azithromycin (odds ratio 0.35 [95% confidence interval 0.17 &ndash; 0.74] and 0.20 [95% confidence interval 0.07 &ndash; 0.58], respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Antibiotic selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;WHO recommends",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (single oral dose of 20",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    or topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    (1 percent eye ointment twice a day for six weeks) for community-wide distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/25\">",
"     25",
"    </a>",
"    ]. Azithromycin is preferred because it is given as a single oral dose, although it is expensive and generally only available as part of the international donation program organized by Pfizer through the International Trachoma Initiative [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/43\">",
"     43",
"    </a>",
"    ]. Azithromycin is considered safe for use in children from the age of six months and during pregnancy.",
"   </p>",
"   <p>",
"    Topical agents may be a useful alternative in areas where oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    is not readily available. The WHO recommends topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    treatment for use in pregnancy. Alternatively, topical azithromycin (1.5 percent) for two or three days may be as effective as oral azithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials have shown that a single dose of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    is as effective as a long course of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    for the treatment of active trachoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/44,46-48\">",
"     44,46-48",
"    </a>",
"    ]. For initial mass treatment, azithromycin and topical tetracycline are also equally effective [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Antibiotic resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of antibiotic resistance is a major concern with any mass treatment program. Chlamydial resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    has not been documented, although it is possible that this may be due to difficulties associated with culturing the bacterium.",
"   </p>",
"   <p>",
"    However, other organisms can develop resistance in the setting of widespread use of antibiotics. S. pneumoniae with resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    was observed briefly following mass azithromycin treatment for trachoma in Nepal and in an Australian Aboriginal community [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. However, one year after administration of single dose azithromycin in a Nepalese village, no S. pneumoniae with azithromycin resistance was detected [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical intervention for trichiasis can improve visual acuity, although it is uncertain whether it prevents blindness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/52-54\">",
"     52-54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Bilamellar tarsal rotation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For individuals with trichiasis, a tarsal rotation procedure is warranted to direct the lashes away from the globe [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/52\">",
"     52",
"    </a>",
"    ]. Early intervention is beneficial as the rate of recurrence is higher in more advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The WHO advocates the bilamellar tarsal rotation procedure (BTR) for both major and minor trichiasis based upon a controlled trial in a trachoma endemic area in Oman [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In this trial, 80 percent of patients with minor trichiasis (one to five eyelashes touching the globe) who underwent BTR had subsequent complete lid closure with no evidence of ingrown eyelashes, compared to only 29 percent of patients treated with epilation (eyelash removal) by electrolysis or cryoablation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/56\">",
"     56",
"    </a>",
"    ]. For major trichiasis (more than five eyelashes touching the globe), BTR was superior to tarsal advance and rotation (favorable outcomes in 77 versus 41 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Surgery program implementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important challenge in the implementation of trachoma surgery is optimization of a community's understanding and utilization of intervention services. A study in the Gambia found that over a one-year period only 23 percent of people with major trichiasis presented for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/58\">",
"     58",
"    </a>",
"    ]. Predictors of poor compliance included unawareness of surgical availability, limited understanding of the benefit of surgery, limited funds, and limited access to transportation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The most important predictors of acceptance were symptoms interfering with quality of life and access to adequate funds [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Recurrent trichiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trichiasis recurrence rate after surgery ranges from 5 to 60 percent in the first two to three years and is more common with severe preoperative disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/55,61-65\">",
"     55,61-65",
"    </a>",
"    ]. Recurrence may be due to progressive natural history of the disease or repeat infection with further scarring. Careful surgical technique can reduce one-year recurrence rates to less than 10 percent.",
"   </p>",
"   <p>",
"    The role of antibiotics for prevention of postoperative recurrence following trichiasis surgery is uncertain. The WHO manual for trichiasis surgery recommends using topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ointment for seven days following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/57\">",
"     57",
"    </a>",
"    ]. A randomized trial conducted in the Gambia assessing adjuvant postoperative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    demonstrated that for those who received azithromycin, at one year there was no reduction in the trichiasis recurrence rate (over 40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/55\">",
"     55",
"    </a>",
"    ]. Subsequently, a randomized trial of 1452 patients in Ethiopia showed that single dose azithromycin reduced postoperative trichiasis recurrence rates by one-third compared with topical tetracycline (7 versus 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/66\">",
"     66",
"    </a>",
"    ]. The benefit of perioperative azithromycin may be more significant in the setting of severe trichiasis (lashes touching the cornea or more than five lashes touching the globe) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/67-69\">",
"     67-69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Corneal transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been limited evaluation of corneal transplant (penetrating keratoplasty) for treating corneal opacification. The outcomes are usually poor because of the extensive corneal vascularization and graft rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Alternatives to surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;For areas without a surgical intervention program, epilation (eyelash removal) has been used to treat trichiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/72\">",
"     72",
"    </a>",
"    ]. Epilation may be beneficial in limiting the development of corneal opacity in patients with moderate to severe entropion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/73\">",
"     73",
"    </a>",
"    ]. However, eyelash removal may need to be repeated daily and the abrasive effect of the eyelash stubble may hasten the onset of blindness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/56\">",
"     56",
"    </a>",
"    ]. Use of an adhesive bandage on the eyelashes to direct them away from the cornea may be more effective than epilation as a temporary measure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other methods of removing eyelashes such as electrolysis, cryotherapy and laser have not proven effective in the treatment of trichiasis, and such technologies are generally not available in trachoma endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Facial cleanliness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with grossly visible nasal discharge, ocular discharge, or flies on their faces are at least twice as likely to have active trachoma as children with clean faces [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been one randomized trial evaluating the efficacy of facial cleanliness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. This trial compared a 30-day course of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ointment antibiotic treatment alone or combined with an intensive community-based health education program to promote face-washing [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/78\">",
"     78",
"    </a>",
"    ]. Antibiotics alone lowered the frequency of active disease in all communities, although the prevalence of active disease was returning toward pretreatment levels by 12 months. However, antibiotics combined with community-based health education significantly reduced the prevalence of intense trachoma (TI) (odds of having severe trachoma in intervention villages were 0.62 compared with villages receiving antibiotics alone).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Environmental improvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. trachomatis is highly infectious and transmitted rapidly in areas of poor hygiene. Spread within a family, it can occur in up to six months after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    treatment; spread between neighboring families, it can occur in 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Environmental improvement is the most weakly defined but perhaps the most important long-term element in trachoma elimination. However, attaining such changes in endemic areas is very difficult.",
"   </p>",
"   <p>",
"    It seems likely that environmental factors ultimately affect transmission as a function of their influence on facial cleanliness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/79\">",
"     79",
"    </a>",
"    ]. Modifications in water use, fly control, latrine use, health education, and proximity to domesticated animals have all been proposed to reduce transmission of C. trachomatis. These changes pose numerous challenges for implementation and rigorous study, although some interesting observations have been made with regard to water use and fly control.",
"   </p>",
"   <p>",
"    Water availability is a critical resource for facial cleanliness. In a study from Tanzania, the risk of trachoma in the household increased with distance from a water source, although there was no association with the quantity of water brought into the house [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/80\">",
"     80",
"    </a>",
"    ]. It may be that the distance between a home and its water supply influences a family's prioritization of water use for hygienic purposes. Thus, modifying the perception of how water should be used in the home may be at least as important as making water more accessible.",
"   </p>",
"   <p>",
"    Household fly density is a potentially amenable risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/75\">",
"     75",
"    </a>",
"    ]. In a single-blind randomized trial in The Gambia, the insecticide deltamethrin was used for fly control in one group of villages while another group was monitored as controls; mass treatment with single dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    was provided to both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/81\">",
"     81",
"    </a>",
"    ]. Deltamethrin significantly reduced fly counts at most time intervals. However, the trachoma rate did not differ significantly at six months or one year (43 versus 44 percent).",
"   </p>",
"   <p>",
"    The authors concluded that insecticide spraying after mass antibiotic treatment does not reduce trachoma prevalence. In comparison, an earlier trial by the same group without mass antibiotic therapy found that insecticide spraying produced a significant mean 56 percent reduction in trachoma prevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The latter trial also evaluated the effect of latrine provision for fly control [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8409/abstract/82\">",
"     82",
"    </a>",
"    ]. Compared with controls, there was a nonsignificant 30 percent reduction in trachoma prevalence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trachoma is a contagious eye infection caused by Chlamydia trachomatis and is the leading infectious cause of blindness worldwide. Active infection with C. trachomatis is mostly seen in young children, while subsequent scarring and blindness (cicatricial disease) is seen in adults. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Identification of an endemic area requires a population assessment to look for the characteristic clinical manifestations of the disease. Once an endemic area has been identified, treatment and elimination require a community-based intervention. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment and elimination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The SAFE strategy (Surgery, Antibiotics, Facial cleanliness and Environmental improvement) is the core tool for trachoma elimination. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment and elimination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      WHO guidelines aimed at elimination of trachoma recommend mass antibiotic treatment when the prevalence of active trachoma among one- to nine-year-old children is greater than 10 percent. Subsequent annual treatment should be administered for three years, at which time the prevalence should be reassessed. Annual treatment should continue until the prevalence drops below 5 percent. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Mass treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When mass treatment is undertaken, we recommend treating with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (single oral dose of 20",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      where available (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). If azithromycin is not available, ophthalmic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      (1 percent eye ointment twice a day for six weeks) can be used. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Antibiotic selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To minimize risk of blindness, patients with trichiasis should have a surgical procedure to protect the cornea from ongoing contact with eyelashes. We recommend that patients with trichiasis undergo a bilamellar tarsal rotation procedure (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Modification of behavior patterns (facial cleanliness) and environmental improvement may reduce the rate of trachoma transmission. It seems likely that environmental factors ultimately affect transmission as a function of their influence on facial cleanliness, so health promotion for clean faces is critical. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Facial cleanliness'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Environmental improvement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/1\">",
"      Thylefors B, N&eacute;grel AD, Pararajasegaram R, Dadzie KY. Global data on blindness. Bull World Health Organ 1995; 73:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/2\">",
"      Taylor HR, Velasco FM, Sommer A. The ecology of trachoma: an epidemiological study in southern Mexico. Bull World Health Organ 1985; 63:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/3\">",
"      Taylor HR, Rapoza PA, West S, et al. The epidemiology of infection in trachoma. Invest Ophthalmol Vis Sci 1989; 30:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/4\">",
"      Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/5\">",
"      Schwab L, Whitfield R Jr, Ross-Degnan D, et al. The epidemiology of trachoma in rural Kenya. Variation in prevalence with lifestyle and environment. Study Survey Group. Ophthalmology 1995; 102:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/6\">",
"      West S, Nguyen MP, Mkocha H, et al. Gender equity and trichiasis surgery in the Vietnam and Tanzania national trachoma control programmes. Br J Ophthalmol 2004; 88:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/7\">",
"      Turner VM, West SK, Mu&ntilde;oz B, et al. Risk factors for trichiasis in women in Kongwa, Tanzania: a case-control study. Int J Epidemiol 1993; 22:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/8\">",
"      Miller K, Pakpour N, Yi E, et al. Pesky trachoma suspect finally caught. Br J Ophthalmol 2004; 88:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/9\">",
"      Wilson M, Keyvan-Larijani E, Millan-Velasco F, et al. The epidemiology of trachoma in Chiapas (Mexico). Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique 1987; :159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/10\">",
"      Dawson CR, Jones BR, Darougar S. Blinding and non-blinding trachoma: assessment of intensity of upper tarsal inflammatory disease and disabling lesions. Bull World Health Organ 1975; 52:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/11\">",
"      Thylefors B, Dawson CR, Jones BR, et al. A simple system for the assessment of trachoma and its complications. Bull World Health Organ 1987; 65:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/12\">",
"      Taylor HR, West SK, Katala S, Foster A. Trachoma: evaluation of a new grading scheme in the United Republic of Tanzania. Bull World Health Organ 1987; 65:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/13\">",
"      Taylor HR, Siler JA, Mkocha HA, et al. The natural history of endemic trachoma: a longitudinal study. Am J Trop Med Hyg 1992; 46:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/14\">",
"      Solomon AW, Peeling RW, Foster A, Mabey DC. Diagnosis and assessment of trachoma. Clin Microbiol Rev 2004; 17:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/15\">",
"      West SK, Mu&ntilde;oz B, Mkocha H, et al. Progression of active trachoma to scarring in a cohort of Tanzanian children. Ophthalmic Epidemiol 2001; 8:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/16\">",
"      Bobo LD, Novak N, Mu&ntilde;oz B, et al. Severe disease in children with trachoma is associated with persistent Chlamydia trachomatis infection. J Infect Dis 1997; 176:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/17\">",
"      Mabey DC, Solomon AW, Foster A. Trachoma. Lancet 2003; 362:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/18\">",
"      Solomon AW, Holland MJ, Alexander ND, et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 2004; 351:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/19\">",
"      Wright HR, Taylor HR. Clinical examination and laboratory tests for estimation of trachoma prevalence in a remote setting: what are they really telling us? Lancet Infect Dis 2005; 5:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/20\">",
"      Solomon AW, Harding-Esch E, Alexander ND, et al. Two doses of azithromycin to eliminate trachoma in a Tanzanian community. N Engl J Med 2008; 358:1870.",
"     </a>",
"    </li>",
"    <li>",
"     Negrel, AD, Taylor, HR, West, S. Guidelines for the rapid assessment for blinding trachoma. Geneva: World Health Organization and International Trachoma initiative 2001; WHO document WHO/PBD/GET/00.8.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/22\">",
"      Negrel AD, Mariotti SP. Trachoma rapid assessment: rationale and basic principles. Community Eye Health 1999; 12:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/23\">",
"      Myatt M, Limburg H, Minassian D, Katyola D. Field trial of applicability of lot quality assurance sampling survey method for rapid assessment of prevalence of active trachoma. Bull World Health Organ 2003; 81:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/24\">",
"      Myatt M, Mai NP, Quynh NQ, et al. Using lot quality-assurance sampling and area sampling to identify priority areas for trachoma control: Viet Nam. Bull World Health Organ 2005; 83:756.",
"     </a>",
"    </li>",
"    <li>",
"     Solomon, AW, Zondervan, M, Kuper, H, et al. Trachoma control: A guide for programme managers. World Health Organization 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/26\">",
"      Kuper H, Solomon AW, Buchan J, et al. A critical review of the SAFE strategy for the prevention of blinding trachoma. Lancet Infect Dis 2003; 3:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/27\">",
"      West SK, Munoz B, Mkocha H, et al. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study. Lancet 2005; 366:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/28\">",
"      Burton MJ, Holland MJ, Faal N, et al. Which members of a community need antibiotics to control trachoma? Conjunctival Chlamydia trachomatis infection load in Gambian villages. Invest Ophthalmol Vis Sci 2003; 44:4215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/29\">",
"      Atik B, Thanh TT, Luong VQ, et al. Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA 2006; 296:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/30\">",
"      Schachter J, West SK, Mabey D, et al. Azithromycin in control of trachoma. Lancet 1999; 354:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/31\">",
"      Fraser-Hurt N, Bailey RL, Cousens S, et al. Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bull World Health Organ 2001; 79:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/32\">",
"      West ES, Munoz B, Mkocha H, et al. Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community. Invest Ophthalmol Vis Sci 2005; 46:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/33\">",
"      Evans JR, Solomon AW. Antibiotics for trachoma. Cochrane Database Syst Rev 2011; :CD001860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/34\">",
"      Porco TC, Gebre T, Ayele B, et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA 2009; 302:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/35\">",
"      Gebre T, Ayele B, Zerihun M, et al. Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial. Lancet 2012; 379:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/36\">",
"      Keenan JD, Ayele B, Gebre T, et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clin Infect Dis 2012; 54:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/37\">",
"      Lietman T, Porco T, Dawson C, Blower S. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat Med 1999; 5:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/38\">",
"      Melese M, Chidambaram JD, Alemayehu W, et al. Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. JAMA 2004; 292:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/39\">",
"      Gill DA, Lakew T, Alemayehu W, et al. Complete elimination is a difficult goal for trachoma programs in severely affected communities. Clin Infect Dis 2008; 46:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/40\">",
"      Melese M, Alemayehu W, Lakew T, et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA 2008; 299:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/41\">",
"      House JI, Ayele B, Porco TC, et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial. Lancet 2009; 373:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/42\">",
"      Keenan JD, Ayele B, Gebre T, et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clin Infect Dis 2011; 52:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/43\">",
"      Mariotti SP. New steps toward eliminating blinding trachoma. N Engl J Med 2004; 351:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/44\">",
"      Mabey D, Fraser-Hurt N, Powell C. Antibiotics for trachoma. Cochrane Database Syst Rev 2005; :CD001860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/45\">",
"      Cochereau I, Goldschmidt P, Goepogui A, et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double-masked clinical trial. Br J Ophthalmol 2007; 91:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/46\">",
"      Bailey RL, Arullendran P, Whittle HC, Mabey DC. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 1993; 342:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/47\">",
"      Dawson CR, Schachter J, Sallam S, et al. A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clin Infect Dis 1997; 24:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/48\">",
"      Tabbara KF, Abu-el-Asrar A, al-Omar O, et al. Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology 1996; 103:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/49\">",
"      Chern KC, Shrestha SK, Cevallos V, et al. Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area. Br J Ophthalmol 1999; 83:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/50\">",
"      Leach AJ, Shelby-James TM, Mayo M, et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis 1997; 24:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/51\">",
"      Gaynor BD, Holbrook KA, Whitcher JP, et al. Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year. Br J Ophthalmol 2003; 87:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/52\">",
"      Yorston D, Mabey D, Hatt S, Burton M. Interventions for trachoma trichiasis. Cochrane Database Syst Rev 2006; :CD004008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/53\">",
"      Reacher MH, Huber MJ, Canagaratnam R, Alghassany A. A trial of surgery for trichiasis of the upper lid from trachoma. Br J Ophthalmol 1990; 74:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/54\">",
"      Adamu Y, Alemayehu W. A randomized clinical trial of the success rates of bilamellar tarsal rotation and tarsotomy for upper eyelid trachomatous trichiasis. Ethiop Med J 2002; 40:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/55\">",
"      Burton MJ, Kinteh F, Jallow O, et al. A randomised controlled trial of azithromycin following surgery for trachomatous trichiasis in the Gambia. Br J Ophthalmol 2005; 89:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/56\">",
"      Reacher MH, Mu&ntilde;oz B, Alghassany A, et al. A controlled trial of surgery for trachomatous trichiasis of the upper lid. Arch Ophthalmol 1992; 110:667.",
"     </a>",
"    </li>",
"    <li>",
"     Reacher, M, Foster, A, Huber, J. Trichiasis surgery for trachoma: the bilamellar tarsal rotation procedure (WHO/PBL/93.29). Geneva, World Health Organization, 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/58\">",
"      Bowman RJ, Faal H, Jatta B, et al. Longitudinal study of trachomatous trichiasis in The Gambia: barriers to acceptance of surgery. Invest Ophthalmol Vis Sci 2002; 43:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/59\">",
"      West S, Lynch M, Munoz B, et al. Predicting surgical compliance in a cohort of women with trichiasis. Int Ophthalmol 1994; 18:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/60\">",
"      Oliva, MS, Munoz, B, Lynch, M, et al. Evaluation of barriers to surgical compliance in the treatment of trichiasis. Int Ophthalmol 1997-1998; 21:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/61\">",
"      Bog H, Yorston D, Foster A. Results of community-based eyelid surgery for trichiasis due to trachoma. Br J Ophthalmol 1993; 77:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/62\">",
"      Bowman RJ, Jatta B, Faal H, et al. Long-term follow-up of lid surgery for trichiasis in the Gambia: surgical success and patient perceptions. Eye (Lond) 2000; 14:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/63\">",
"      Khandekar R, Mohammed AJ, Courtright P. Recurrence of trichiasis: a long-term follow-up study in the Sultanate of Oman. Ophthalmic Epidemiol 2001; 8:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/64\">",
"      Thanh TT, Khandekar R, Luong VQ, Courtright P. One year recurrence of trachomatous trichiasis in routinely operated Cuenod Nataf procedure cases in Vietnam. Br J Ophthalmol 2004; 88:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/65\">",
"      Burton MJ, Bowman RJ, Faal H, et al. Long term outcome of trichiasis surgery in the Gambia. Br J Ophthalmol 2005; 89:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/66\">",
"      West SK, West ES, Alemayehu W, et al. Single-dose azithromycin prevents trichiasis recurrence following surgery: randomized trial in Ethiopia. Arch Ophthalmol 2006; 124:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/67\">",
"      West S, Alemayehu W, Munoz B, Gower EW. Azithromycin prevents recurrence of severe trichiasis following trichiasis surgery: STAR trial. Ophthalmic Epidemiol 2007; 14:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/68\">",
"      Zhang H, Kandel RP, Atakari HK, Dean D. Impact of oral azithromycin on recurrence of trachomatous trichiasis in Nepal over 1 year. Br J Ophthalmol 2006; 90:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/69\">",
"      Woreta F, Munoz B, Gower E, et al. Three-year outcomes of the surgery for trichiasis, antibiotics to prevent recurrence trial. Arch Ophthalmol 2012; 130:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/70\">",
"      Kocak-Midillioglu I, Akova YA, Ko&ccedil;ak-Altintas AG, et al. Penetrating keratoplasty in patients with corneal scarring due to trachoma. Ophthalmic Surg Lasers 1999; 30:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/71\">",
"      Yorston D, Wood M, Foster A. Penetrating keratoplasty in Africa: graft survival and visual outcome. Br J Ophthalmol 1996; 80:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/72\">",
"      al-Rifai KM. Trachoma through history. Int Ophthalmol 1988; 12:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/73\">",
"      West ES, Munoz B, Imeru A, et al. The association between epilation and corneal opacity among eyes with trachomatous trichiasis. Br J Ophthalmol 2006; 90:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/74\">",
"      Graz B, Xu JM, Yao ZS, et al. Trachoma: can trichiasis be treated with a sticking-plaster? A randomized clinical trial in China. Trop Med Int Health 1999; 4:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/75\">",
"      Taylor HR, West SK, Mmbaga BB, et al. Hygiene factors and increased risk of trachoma in central Tanzania. Arch Ophthalmol 1989; 107:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/76\">",
"      Hsieh YH, Bobo LD, Quinn TC, West SK. Risk factors for trachoma: 6-year follow-up of children aged 1 and 2 years. Am J Epidemiol 2000; 152:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/77\">",
"      Ejere H, Alhassan MB, Rabiu M. Face washing promotion for preventing active trachoma. Cochrane Database Syst Rev 2004; :CD003659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/78\">",
"      West S, Mu&ntilde;oz B, Lynch M, et al. Impact of face-washing on trachoma in Kongwa, Tanzania. Lancet 1995; 345:155.",
"     </a>",
"    </li>",
"    <li>",
"     Taylor, HR. Trachoma. A Blinding Scourge from the Bronze Age to the Twenty-first Century, Centre for Eye Research Australia, Melbourne 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/80\">",
"      West S, Lynch M, Turner V, et al. Water availability and trachoma. Bull World Health Organ 1989; 67:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/81\">",
"      West SK, Emerson PM, Mkocha H, et al. Intensive insecticide spraying for fly control after mass antibiotic treatment for trachoma in a hyperendemic setting: a randomised trial. Lancet 2006; 368:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8409/abstract/82\">",
"      Emerson PM, Lindsay SW, Alexander N, et al. Role of flies and provision of latrines in trachoma control: cluster-randomised controlled trial. Lancet 2004; 363:1093.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3026 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-2522EA1FE6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_13_8409=[""].join("\n");
var outline_f8_13_8409=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Active trachoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Cicatricial disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Grading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SURVEY ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT AND ELIMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Mass treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Antibiotic selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Antibiotic resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Bilamellar tarsal rotation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Surgery program implementation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Recurrent trichiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Corneal transplant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Alternatives to surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Facial cleanliness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Environmental improvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3026\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3026|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/50/19238\" title=\"figure 1\">",
"      Regions of endemic trachoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/57/17310\" title=\"figure 2\">",
"      Epidemiology of trachoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/19/28990\" title=\"figure 3\">",
"      History of C trachomatis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/41/1681\" title=\"figure 4\">",
"      Conjunctival anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3026|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/57/27540\" title=\"picture 1\">",
"      Active trachoma follicles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/32/7686\" title=\"picture 2\">",
"      Active trachoma inflam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/52/2885\" title=\"picture 3\">",
"      Conjunctival scarring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/26/27046\" title=\"picture 4\">",
"      Trichiasis and sequelae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3026|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/15/11515\" title=\"table 1\">",
"      Clinical signs trachoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=related_link\">",
"      Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_13_8410="Angiodysplasia of the gastrointestinal tract";
var content_f8_13_8410=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Angiodysplasia of the gastrointestinal tract",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/13/8410/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/13/8410/contributors\">",
"     Marcos C Pedrosa, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/13/8410/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/13/8410/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/13/8410/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/13/8410/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/13/8410/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aberrant blood vessels are frequently found in the gastrointestinal tract, where they are probably more common than anywhere else in the body. Some are present from birth or develop as part of inherited syndromes, but the vast majority are acquired later in life. The reasons for the distortion of vascular structures observed with advancing age are poorly understood.",
"   </p>",
"   <p>",
"    Inconsistent taxonomy of vascular anomalies in the gastrointestinal tract, along with a common presentation of gastrointestinal bleeding from different vascular abnormalities, has led to significant confusion in the medical literature [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The diagnosis of a vascular anomaly can be based upon endoscopic findings, histologic characteristics, or association with systemic diseases.",
"   </p>",
"   <p>",
"    Vascular anomalies can be divided into three broad categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vascular tumors or angiomas, which can be benign (such as hemangiomas) or malignant (such as Kaposi's sarcoma or angiosarcoma)",
"     </li>",
"     <li>",
"      Vascular anomalies associated with congenital or systemic diseases, such as blue rubber bleb nevus syndrome, Klippel-Trenaunay-Weber syndrome, Ehlers-Danlos syndrome, the CREST variant of scleroderma, and hereditary hemorrhagic telangiectasias (Osler-Weber-Rendu syndrome)",
"     </li>",
"     <li>",
"      Acquired and sporadic lesions, such as angiodysplasias, gastric antral vascular ectasias, radiation-induced vascular ectasias, and Dieulafoy's lesions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Angiodysplasias are the most common vascular anomalies encountered in the gastrointestinal tract. The pathology, clinical manifestations, diagnosis, and treatment of angiodysplasia will be reviewed here. The evaluation of occult and obscure gastrointestinal bleeding, as well as Dieulafoy's lesions and gastric antral vascular ectasias, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11336?source=see_link\">",
"     \"Evaluation of occult gastrointestinal bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link\">",
"     \"Evaluation of obscure gastrointestinal bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=see_link\">",
"     \"Uncommon causes of upper gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terms angiodysplasia, arteriovenous malformation, angioectasia, and vascular ectasia have been used synonymously. Angiodysplasias are usually distinguished from telangiectasias, which, while anatomically similar, are usually referred to in the context of systemic or congenital diseases. In addition, some authors use angioectasia as a generic term, reserving the term angiodysplasia for colonic lesions.",
"   </p>",
"   <p>",
"    Since most vascular abnormalities are detected during endoscopy, a taxonomy based upon endoscopic appearance has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/3\">",
"     3",
"    </a>",
"    ]. The classification system recognizes the location, size, and number of angiodysplasias (",
"    <a class=\"graphic graphic_table graphicRef67055 \" href=\"UTD.htm?21/16/21771\">",
"     table 1",
"    </a>",
"    ). With the advent of newer endoscopic techniques, there has been an attempt to classify the lesions found in the small bowel according to size, overt bleeding, and surrounding vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/4\">",
"     4",
"    </a>",
"    ]. However, these classifications are not widely used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=see_link\">",
"     \"Wireless video capsule endoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24649?source=see_link\">",
"     \"Overview of deep small bowel enteroscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal (GI) angiodysplasia is most often detected in patients older than 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/5-8\">",
"     5-8",
"    </a>",
"    ], although presentation in patients in their 30s has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/9\">",
"     9",
"    </a>",
"    ]. The prevalence of GI angiodysplasia in the overall population is not well known. In a report that pooled three prospective studies of colonoscopic screening for neoplasia in healthy asymptomatic adults (older than 50 years, mean age 62 years), angiodysplasia was detected in only 8 of 964 patients (0.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/10\">",
"     10",
"    </a>",
"    ]. The prevalence may be higher with more sensitive techniques, such as injection studies in resected colon specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence is increased in patients with end-stage renal disease, von Willebrand's disease, and possibly aortic stenosis. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Conditions associated with angiodysplasia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Approximately 40 to 60 percent of patients have more than one angiodysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/6,12\">",
"     6,12",
"    </a>",
"    ]. While they are usually in the same portion of the GI tract, synchronous lesions elsewhere in the GI tract are found in approximately 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In one series of patients thought to be bleeding from angiodysplasia of the colon, small bowel angiodysplasia was detected in 23 percent, either at the original laparotomy or during investigation for recurrent bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/14\">",
"     14",
"    </a>",
"    ]. This illustrates the point that a given angiodysplasia can only be confidently considered the source of GI blood loss if it is seen to be actively bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Conditions associated with angiodysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of angiodysplasia is increased in older populations, in patients with GI bleeding, and in patients with certain predisposing conditions, such as end-stage renal disease, von Willebrand disease, and possibly aortic stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     End-stage renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiodysplasia account for about 20 and 30 percent of episodes of upper and lower GI bleeding, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/15\">",
"     15",
"    </a>",
"    ], and for approximately one-half of recurrent episodes of upper GI bleeding in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/16\">",
"     16",
"    </a>",
"    ]. They can occur anywhere along the GI tract and are usually multiple [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14101?source=see_link\">",
"     \"Complications of hemodialysis in the elderly patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reason for the increased prevalence among patients with end-stage renal disease is unknown. One possible explanation is that the lesions are not more common, but are instead detected more frequently because of the increased risk of bleeding associated with uremia-induced platelet dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=see_link\">",
"     \"Platelet dysfunction in uremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Von Willebrand disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between angiodysplasia and congenital or acquired von Willebrand disease (vWD) has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. However, similar to end-stage renal disease, this association may reflect an increased tendency for angiodysplasia to become clinically evident because of an underlying coagulopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link\">",
"     \"Classification and pathophysiology of von Willebrand disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Aortic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding from angiodysplasia in patients with aortic stenosis (AS) has been called Heyde's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/19\">",
"     19",
"    </a>",
"    ]. While it has been repeatedly reported, some aspects remain controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/20-23\">",
"     20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In support of the relationship of angiodysplasia with AS is the observation that bleeding improves in most patients after aortic valve replacement (AVR) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. One report, for example, evaluated 91 patients with AS and obscure chronic GI bleeding, presumably from angiodysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/24\">",
"     24",
"    </a>",
"    ]. Sixteen of these patients underwent AVR for AS during follow-up of 8 to 12 years, with cessation of chronic gastrointestinal blood loss in all but one. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link&amp;anchor=H27#H27\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\", section on 'Bleeding tendency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate issue is whether the prevalence of AS is increased in patients with angiodysplasia. The results of small case control and retrospective studies have been equivocal:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report compared echocardiographic findings in 40 patients with angiodysplasia with 37 matched controls [",
"      <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/28\">",
"       28",
"      </a>",
"      ]. None of the patients in either group had evidence of aortic stenosis.",
"     </li>",
"     <li>",
"      A similar observation was made in a retrospective series of 59 patients with angiodysplasia, only one of whom had echocardiographic evidence of aortic stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      By contrast, a third report of 73 patients with angiodysplasia who had undergone echocardiography did suggest an association with AS [",
"      <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/30\">",
"       30",
"      </a>",
"      ]. In that report, the prevalence of AS was 32 percent, which was significantly higher than the prevalence among the general population of patients who undergo echocardiography (approximately 14 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classically described in the colon, angiodysplasia can occur throughout the gastrointestinal tract. There may be multiple angiodysplasias in one gastrointestinal region or they may coexist in several different gastrointestinal locations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiodysplasias are composed of ectatic, dilated, thin-walled vessels that are lined by endothelium alone or endothelium along with small amounts of smooth muscle. Studies in which casts of angiodysplasias were made by injecting a silicone material demonstrated that the most prominent feature in angiodysplasias is the presence of dilated, tortuous submucosal veins [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Small arteriovenous communications are also present and are due to incompetence of the precapillary sphincter. Enlarged arteries may be seen in larger angiodysplasias and may be associated with arteriovenous fistulas, which explains why bleeding can be brisk in some patients (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52754 \" href=\"UTD.htm?38/41/39583\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Histologic confirmation is often difficult. When obtained, it shows dilated vessels in the mucosa and submucosa, sometimes covered by only a single layer of surface epithelium (",
"    <a class=\"graphic graphic_picture graphicRef74301 \" href=\"UTD.htm?2/53/2905\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Venous obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of angiodysplasia is not well understood. However, a proposed theory is that angiodysplasia develop due to intermittent, recurrent low-grade obstruction of submucosal veins at the level of the muscularis propria (",
"    <a class=\"graphic graphic_figure graphicRef76997 \" href=\"UTD.htm?20/13/20690\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/31\">",
"     31",
"    </a>",
"    ]. Over years, the obstruction results in dilatation and tortuosity of the draining areas (ie, submucosal vessels, venules, and superficial capillaries).",
"   </p>",
"   <p>",
"    The venous obstruction hypothesis is consistent with the observation that angiodysplasia often occurs in the right colon where wall tension is highest. This increased wall tension selectively compresses thin-walled veins, while allowing normal flow through the thicker-walled higher-pressure arterioles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Angiogenic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased expression of angiogenic factors has been found in human colonic angiodysplasias [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/33\">",
"     33",
"    </a>",
"    ]. However, the relationship of this observation to pathogenesis is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acquired von Willebrand disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible mechanism by which aortic stenosis (AS) may lead to the development of angiodysplasia is through the development of an acquired form of von Willebrand disease (vWD) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/27,34,35\">",
"     27,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acquired vWD is thought to result from mechanical disruption of von Willebrand multimers during turbulent passage through the narrowed valve and from a von Willebrand factor interaction with platelets that triggers platelet clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/27,36,37\">",
"     27,36,37",
"    </a>",
"    ]. This raises the possibility that the increased prevalence of angiodysplasia in patients with AS is due to increased detection because these patients are more likely to present with bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link&amp;anchor=H27#H27\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\", section on 'Bleeding tendency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiodysplasia may be found during evaluation of gastrointestinal (GI) bleeding or it may be discovered incidentally during an endoscopic evaluation being performed for other reasons. If bleeding occurs, the bleeding tends be recurrent and chronic [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/38\">",
"     38",
"    </a>",
"    ]. However, marked acute bleeding causing orthostasis or hypotension can occur.",
"   </p>",
"   <p>",
"    GI bleeding can occur at a multiple sites within the GI tract, including the colon, small intestine, and stomach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Colon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonic lesions are found most often in the right colon. The following distribution was noted in a series that included 59 patients with colonic angiodysplasia, 47 of whom were asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cecum &ndash; 37 percent",
"     </li>",
"     <li>",
"      Ascending colon &ndash; 17 percent",
"     </li>",
"     <li>",
"      Transverse colon &ndash; 7 percent",
"     </li>",
"     <li>",
"      Descending colon &ndash; 7 percent",
"     </li>",
"     <li>",
"      Sigmoid colon &ndash; 18 percent",
"     </li>",
"     <li>",
"      Rectum &ndash; 14 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other series of patients with angiodysplasia have found even higher rates of right-sided lesions (up to 89 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/7,40,41\">",
"     7,40,41",
"    </a>",
"    ]. The risk of subsequent bleeding in patients who are found to have nonbleeding colonic angiodysplasia is not well established. The number of lesions and the presence of coexisting coagulopathies or platelet dysfunction may be important determinants. Patients who have bled from colonic angiodysplasia are at increased risk for subsequent bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7272?source=see_link\">",
"     \"Etiology of lower gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Small intestine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiodysplasia can be found throughout the small intestine. It is frequently detected when patients undergo evaluation for gastrointestinal bleeding of unclear etiology, despite upper endoscopy and colonoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link\">",
"     \"Evaluation of obscure gastrointestinal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 5 percent of patients presenting with gastrointestinal hemorrhage do not have a source identified by an initial upper endoscopy or colonoscopy; a potential source will be found in the small intestine in three-quarters of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/42\">",
"     42",
"    </a>",
"    ]. Small intestine vascular lesions are responsible for approximately 40 percent of episodes of small intestinal bleeding in patients over the age of 40 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Stomach and duodenum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiodysplasia of the stomach or duodenum has been incriminated as the cause of blood loss in 4 to 7 percent of patients with gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/5,6,12\">",
"     5,6,12",
"    </a>",
"    ]. Such patients may present with either occult bleeding or overt bleeding. In addition, angiodysplasia may be detected as an incidental finding.",
"   </p>",
"   <p>",
"    The frequency of clinical manifestations was evaluated in a study of 41 patients with gastric or duodenal angiodysplasia found during upper endoscopy performed for a variety of indications [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/43\">",
"     43",
"    </a>",
"    ]. The lesions were associated with overt bleeding in 11 patients (27 percent) and with occult bleeding in 9 (22 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/43\">",
"     43",
"    </a>",
"    ]. The remaining 21 patients (51 percent) did not have a history of occult or overt bleeding, and the angiodysplasia was considered to be incidental finding. The risk that incidentally found gastric or duodenal angiodysplasia will subsequently bleed is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiodysplasia is usually diagnosed by endoscopy being done to evaluate GI bleeding, but in some cases, radiographic imaging or surgery may be required for detection. The aggressiveness of the diagnostic approach should be individualized depending upon the clinical circumstances. As an example, further evaluation probably is not necessary in a patient with a negative upper and lower endoscopy and negative wireless capsule endoscopy, unless the patient is bleeding severely enough to require transfusions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link\">",
"     \"Evaluation of obscure gastrointestinal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic options for the diagnosis of angiodysplasia include upper endoscopy, colonoscopy, wireless capsule endoscopy, and deep small bowel enteroscopy (eg, double balloon enteroscopy). Because angiodysplasia can be located throughout the GI tract, a combination of endoscopic techniques may be necessary.",
"   </p>",
"   <p>",
"    Angiodysplasias characteristically appear as small (5 to 10 mm), flat, cherry red lesions with a fern-like pattern of arborizing, ectatic blood vessels radiating from a central vessel (",
"    <a class=\"graphic graphic_picture graphicRef50137 graphicRef73541 \" href=\"UTD.htm?17/23/17778\">",
"     picture 2A-B",
"    </a>",
"    ). The characteristic appearance may be more evident in the colon. Small intestinal lesions are often smaller than those seen in other parts of the GI tract. The fern-like pattern should be specifically looked for, since other erythematous mucosal lesions or normal blood vessels can be mistaken for angiodysplasias [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity of colonoscopy for the detection of angiodysplasia is unknown since angiography would be required as a gold standard. However, it is estimated to exceed 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/7\">",
"     7",
"    </a>",
"    ]. Angiodysplasia may be difficult to visualize during colonoscopy in patients who do not have an optimal bowel preparation or when lesions are situated behind a haustral fold. In addition, transiently decreased mucosal blood flow due to the administration of opioid sedation or air insufflation may make angiodysplasia less visible. It is therefore possible that administration of an opioid antagonist or the withdrawal of air during the examination may improve their detection.",
"   </p>",
"   <p>",
"    Administration of an opioid antagonist was evaluated in a series of 144 patients older than 60 years of age who underwent colonoscopy for occult or overt bleeding or iron deficiency anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/45\">",
"     45",
"    </a>",
"    ]. Angiodysplasia was detected in 12 patients (8 percent). After reaching and inspecting the cecum, patients were given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    hydrochloride (0.4 to 0.8 mg intravenously). Initially inapparent angiodysplasia became visible in an additional four patients.",
"   </p>",
"   <p>",
"    However, it is unclear if this approach would lead to significant clinical benefit given the uncertainty that a nonbleeding angiodysplasia is the cause of bleeding during standard colonoscopy, much less one that has been augmented by giving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    . Furthermore, reversal of opioid analgesia may cause an uncomfortable subsequent examination due to lack of analgesia and can precipitate acute narcotic withdrawal in patients who use narcotics chronically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Radiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging, such as helical computed tomography (CT) or magnetic resonance angiography, may provide another method to diagnose angiodysplasia. The accuracy of CT angiography was estimated in a study that included 26 patients suspected of having colonic angiodysplasia who underwent standard colonoscopy, CT angiography, and standard angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/46\">",
"     46",
"    </a>",
"    ]. Compared to the results of colonoscopy and standard angiography, the sensitivity and specificity of CT angiography were 70 and 100 percent, respectively. Further studies are needed to better define the role of this technique in the management of patients with GI bleeding.",
"   </p>",
"   <p>",
"    In cases of recurrent GI bleeding or persistent iron-deficiency anemia where no source has been identified with less invasive means (eg, endoscopy and CT angiography), angiography, may establish the diagnosis and possibly permit therapy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52754 \" href=\"UTD.htm?38/41/39583\">",
"     image 1",
"    </a>",
"    ). The evaluation of patients with obscure gastrointestinal bleeding is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link\">",
"     \"Evaluation of obscure gastrointestinal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Intraoperative enteroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients with a negative endoscopic and radiographic evaluation, the bleeding will be significant enough to require further evaluation. One approach is intraoperative enteroscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link&amp;anchor=H9#H9\">",
"     \"Evaluation of obscure gastrointestinal bleeding\", section on 'Intraoperative enteroscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several issues must be addressed with regard to the treatment of angiodysplasia:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How should incidentally found lesions be managed?",
"     </li>",
"     <li>",
"      In patients being evaluated for occult or overt gastrointestinal bleeding, should nonbleeding lesions found on endoscopy be treated?",
"     </li>",
"     <li>",
"      What is the efficacy of endoscopic treatment?",
"     </li>",
"     <li>",
"      Which patients require surgery?",
"     </li>",
"     <li>",
"      Is there a role for treatment with hormonal therapy?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Incidentally found lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiodysplasia that is detected during screening colonoscopy should",
"    <strong>",
"     not",
"    </strong>",
"    be treated. As discussed above, the risk of subsequent bleeding is unknown, but is probably low given that angiodysplasia is often found in asymptomatic patients (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Colon'",
"    </a>",
"    above). In addition, a patient found to have a single angiodysplasia during a routine endoscopic examination probably has additional undetected lesions in the colon or in other portions of the GI tract (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Epidemiology'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Nonbleeding angiodysplasias in patients with GI bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;While it is agreed that actively bleeding lesions require treatment, the management of nonbleeding lesions is less clear since it frequently cannot be determined whether an identified nonbleeding angiodysplasia was the cause of either occult or overt bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Occult bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite endoscopic evaluation, the cause of occult GI bleeding remains obscure in 10 to 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The proportion of patients with an unclear source of bleeding may be even higher, since it is often uncertain whether specific findings (such as small polyps, gastritis, or esophagitis) are actually the cause of bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link\">",
"     \"Evaluation of obscure gastrointestinal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar uncertainty exists for angiodysplasia detected during evaluation of occult bleeding or iron deficiency anemia, since angiodysplasia is a common finding in patients without gastrointestinal bleeding. Angiodysplasia is more likely to be the cause of occult bleeding in patients who have ongoing occult bleeding, multiple lesions, or a bleeding diathesis. As a result, a graduated approach to treatment is reasonable in these patients.",
"   </p>",
"   <p>",
"    We suggest treating angiodysplasia found during upper endoscopy or colonoscopy in patients with occult bleeding, even if the lesions are not bleeding at the time of the endoscopy. If needed, patients should also be started on iron replacement therapy. If the anemia persists despite these measures, more aggressive diagnostic and therapeutic options can be considered (eg, deep small bowel enteroscopy or intraoperative enteroscopy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link\">",
"     \"Evaluation of obscure gastrointestinal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Overt bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;It can be difficult to determine if a nonbleeding angiodysplasia is the cause of overt bleeding in a patient who has both angiodysplasia and diverticula. This clinical scenario is common since both occur in the same age group [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38679?source=see_link\">",
"     \"Colonic diverticular bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bleeding is more likely to be due to angiodysplasia rather than diverticula if [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are multiple recurrent episodes of overt bleeding",
"     </li>",
"     <li>",
"      The patient has a condition that predisposes to angiodysplasia, such as end-stage renal disease (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Conditions associated with angiodysplasia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      The bleeding appears to be venous in origin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, bleeding from the left colon is more likely to be diverticular in origin. Although right-sided diverticula are more prone to bleeding than those in the left colon, bleeding from angiodysplasia is almost always from the cecum or ascending colon, as the right colon is the most common site of angiodysplasia. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Colon'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Despite the fact that it can be difficult to determine if overt bleeding is due to diverticula or angiodysplasia, if nonbleeding angiodysplasia is found during the evaluation of overt bleeding, we suggest that it be treated unless bleeding from a diverticulum is identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Endoscopic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of endoscopic treatments can be used to treat angiodysplasia, with approaches employing cautery being the most widely used. The approach that is chosen depends upon the location and mode of access to the lesion, the experience of the endoscopist, and the availability of equipment. Endoscopic therapy should be performed cautiously in the right colon, which is thin-walled and more likely to perforate during treatment than other sections of the gastrointestinal tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Argon plasma coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Argon plasma coagulation (APC) uses high frequency energy transmitted to tissue by ionized gas. This technique has been used for a variety of bleeding lesions, including angiodysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. APC is safe and is the most common and most successful method used to treat angiodysplasia, especially in the right colon [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/54\">",
"     54",
"    </a>",
"    ]. Its popularity is due to its ease of use (especially for large superficial lesions), low cost, and reported limited depth of coagulation, although the depth of coagulation may be deeper than is commonly reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=see_link\">",
"     \"Argon plasma coagulation in the management of gastrointestinal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In two in vivo animal model studies, injury to the muscularis propria was noted frequently and correlated closely with power, duration, and total energy delivered. There were no perforations seen in either of these small studies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. However, perforation of the cecum has been reported in clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Submucosal saline injection prior to treatment with APC may protect against deep wall injury [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/57\">",
"     57",
"    </a>",
"    ]. In a study of ten colonic angiodysplasias, submucosal injection with a",
"    <span class=\"nowrap\">",
"     saline/epinephrine",
"    </span>",
"    solution prior to APC was done easily and quickly [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A full colon preparation is recommended when performing APC, even in the rectum and sigmoid colon due to the risk of colonic gas explosion from inadequate preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Electrocoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar or heater probe coagulation is effective for treatment of angiodysplasia in the colon or upper gastrointestinal tract (",
"    <a class=\"graphic graphic_table graphicRef71455 \" href=\"UTD.htm?14/9/14492\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/60\">",
"     60",
"    </a>",
"    ]. The risk of perforation with heater probe coagulation may be increased in the colon and small bowel beyond the duodenum. These techniques have generally replaced monopolar coagulation, which may be less effective and is associated with an increased rate of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Mechanical hemostasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical hemostatic methods such as endoscopic clips have been described for the treatment of localized lesions. These methods have the advantage of avoiding tissue injury, which may be particularly desirable in patients taking anticoagulants",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antiplatelet agents, or in patients with coagulation defects. These techniques have only been described in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/62,63\">",
"     62,63",
"    </a>",
"    ], so their efficacy is not established.",
"   </p>",
"   <p>",
"    Band ligation is another mechanical method that has been described in case reports. It has been used to treat angiodysplasia of the stomach and small bowel [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection sclerotherapy and lasers are other therapies for angiodysplasia that are infrequently used.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Injection of a sclerosant (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1603?source=see_link\">",
"       sodium tetradecyl",
"      </a>",
"      sulfate or ethanolamine) has been used to obliterate lesions in the upper digestive tract and the colon [",
"      <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/43,66\">",
"       43,66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Argon and Nd-YAG lasers have been used in the treatment of angiodysplasia throughout the gastrointestinal tract [",
"      <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/67-69\">",
"       67-69",
"      </a>",
"      ]. However, these techniques require expensive equipment and specific training and complications have occurred in up to 15 percent of patients treated with Nd-YAG laser in the right colon [",
"      <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining the impact of treatment for angiodysplasia is difficult due to the variable natural history of angiodysplasia and the inconsistent impact that bleeding can have on quality of life. Prospective controlled trials have not been performed.",
"   </p>",
"   <p>",
"    Results from older studies were mixed. In two initial observational studies of 16 patients with angiodysplasia requiring transfusion and 33 patients with angiodysplasia and obscure iron deficiency anemia, more than one-half of patients had recurrent bleeding episodes after surgery, endoscopic therapy, or transfusions alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More promising results were noted in a report of 83 patients thought to have bled from small intestinal angiodysplasia who were followed for approximately 30 months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/60\">",
"     60",
"    </a>",
"    ]. Fifty-five patients received treatment with electrocautery during push enteroscopy and were compared with 28 patients who were treated conservatively. The treated group had a significantly lower transfusion requirement during follow-up (0.32 versus 2.16 units of blood per month).",
"   </p>",
"   <p>",
"    In a more recent prospective study of 100 patients with colonic angiodysplasia, treatment with argon plasma coagulation led to stabilization of hemoglobin levels in 85 patients with a mean follow-up of 20 months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/72\">",
"     72",
"    </a>",
"    ]. Only one patient in that study went on to require surgical treatment for angiodysplasia.",
"   </p>",
"   <p>",
"    Patients with bleeding diatheses have worse outcomes, regardless of the therapy employed, if the underlying coagulation defect cannot be reversed. Because endoscopic electrocoagulation can result in worsening bleeding in patients with a coagulopathy, we favor a mechanical hemostatic method, such endoscopic clips [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/73\">",
"     73",
"    </a>",
"    ], if the coagulation defect cannot be corrected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiography may localize the site of active bleeding and permit embolization or infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    to stop the bleeding. Although embolization with microcoils may be more successful than vasopressin infusion, it is associated with a higher rate of complications. Angiography is generally reserved for patients with life threatening bleeding who are not surgical candidates, or for those in whom localization of lesions is desired prior to surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24616?source=see_link\">",
"     \"Angiographic control of nonvariceal gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection is definitive therapy for lesions that have been clearly identified as the source of bleeding. However, recurrent bleeding can occur from lesions elsewhere in the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/5,41,43\">",
"     5,41,43",
"    </a>",
"    ]. In a series that included 16 patients who underwent right hemicolectomy for bleeding from angiodysplasia, unexplained recurrent bleeding developed in six (38 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/41\">",
"     41",
"    </a>",
"    ]. The causes of recurrent bleeding after surgery included incomplete resection of the initial angiodysplastic lesion, occult lesions missed on arteriography and left behind at surgery, and the appearance of new lesions after surgery.",
"   </p>",
"   <p>",
"    Surgery can be considered for patients with large transfusion requirements or life-threatening hemorrhage from a clearly identified site. Preoperative or intraoperative enteroscopy or angiography may be helpful for localizing lesions. As discussed above, aortic valve surgery may reduce bleeding in patients with angiodysplasia and aortic stenosis. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Acquired von Willebrand disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Hormonal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen (with or without progesterone) has been used to control obscure gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome), end-stage renal disease, and von Willebrand disease. The use of hormonal therapy in these disorders is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=see_link&amp;anchor=H12#H12\">",
"     \"Platelet dysfunction in uremia\", section on 'Estrogen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of von Willebrand disease\", section on 'Estrogen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=see_link&amp;anchor=H12129701#H12129701\">",
"     \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\", section on 'Hormones and antifibrinolytic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A crossover study of 43 patients who acted as their own controls suggested a benefit in patients with bleeding from sporadic angiodysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/75\">",
"     75",
"    </a>",
"    ]. However, this has not been confirmed in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. The best data come from a multicenter, placebo-controlled trial involving 72 noncirrhotic patients bleeding from documented angiodysplasia; there was no benefit from hormone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/76\">",
"     76",
"    </a>",
"    ]. Based on these findings, there seems to be little role for hormonal therapy in patients with sporadic angiodysplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Angiogenesis inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibitors of angiogenesis, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , may play a role in the treatment of vascular malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/78\">",
"     78",
"    </a>",
"    ]. The successful use of thalidomide has been described in a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/79\">",
"     79",
"    </a>",
"    ], case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/80,81\">",
"     80,81",
"    </a>",
"    ], and observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=see_link&amp;anchor=H12129737#H12129737\">",
"     \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\", section on 'Angiogenesis inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized trial compared treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    with iron supplementation in 55 patients with recurrent or refractory bleeding from gastrointestinal vascular malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/79\">",
"     79",
"    </a>",
"    ]. Patients were assigned to either receive thalidomide (25 mg four times per day) or ferrous succinate (100 mg four times per day). Patients were treated for a total of four months and then were followed for one year after treatment. A response to treatment was defined by a decrease in bleeding episodes of at least 50 percent within the first year of follow-up. Patients treated with thalidomide were more likely than those treated with iron to have a response to treatment (71 versus 4 percent). In addition, patients treated with thalidomide were more likely to have their bleeding stop (46 versus 0 percent), less likely to be dependent upon blood transfusions (11 versus 48 percent), and less likely to be hospitalized for bleeding (39 versus 100 percent). The most common adverse events seen in the thalidomide group included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatigue (32 percent)",
"     </li>",
"     <li>",
"      Constipation (25 percent)",
"     </li>",
"     <li>",
"      Dizziness (21 percent)",
"     </li>",
"     <li>",
"      Peripheral edema (14 percent)",
"     </li>",
"     <li>",
"      Abdominal distension (4 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional adverse events that were noted in one patient each (four percent) included abdominal distension, leukopenia, thrombocytopenia, bradycardia, numb limb, somnolence, headache, hand trembling, tinnitus, rash, pruritus, dry eye, blurred vision, vaginal discharge, and herpes zoster. Adverse events seen in the iron group included fatigue (11 percent), constipation (11 percent), dizziness (7 percent), and abdominal distension (7 percent). No severe adverse events were reported in this small trial, but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    has been associated with venous thrombosis, peripheral neuropathy, liver toxicity, and fulminant hepatic failure, in addition to causing birth defects [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=see_link&amp;anchor=H25#H25\">",
"     \"Genetic and environmental causes of birth defects\", section on 'Drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these results, it appears reasonable to treat patients with recurrent or refractory bleeding with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    if they have failed to respond to other therapies. However, until other studies confirm these results, we suggest it only be used as a last resort in transfusion dependent patients. In addition, due to its teratogenic effects, thalidomide must not be used in women of child bearing potential who are unable to use two reliable forms of birth control for at least one month prior to starting thalidomide and for one month after stopping it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Octreotide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    given subcutaneously (typically 50 to 100 mcg twice per day) in the treatment of angiodysplasia has been evaluated in case reports, a small series, and a meta-analysis in which a response has been observed in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/86-93\">",
"     86-93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 32 patients receiving 50 mcg twice a day, the actuarial probability of remaining free of rebleeding at one and two years was 77 and 68 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/91\">",
"     91",
"    </a>",
"    ]. This was higher than the probability seen with patients receiving an oral placebo as part of a separate study (55 and 36 percent), respectively. However, the groups did not differ with regard to the number of bleeding episodes or transfusion requirements, although patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    had a lower requirement for iron.",
"   </p>",
"   <p>",
"    A meta-analysis summarized the results of three prospective studies with a total of 62 patients who were treated with a somatostatin analog for recurrent bleeding from gastrointestinal vascular malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/92\">",
"     92",
"    </a>",
"    ]. The analysis found that 76 percent of patients responded to the therapy. In addition, transfusion requirements were significantly lower after patients started long-term treatment compared with baseline. Patients with refractory bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inaccessible lesions may benefit from long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A long-acting form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (octreotide-LAR) is available that can be given intramuscularly once per month. It was studied in 15 patients with recurrent bleeding from gastrointestinal angiodysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/13/8410/abstract/94\">",
"     94",
"    </a>",
"    ]. Outcomes were compared between a six-month period while on treatment and the six months prior to starting treatment. The percentage of patients who experienced a bleeding event was lower during treatment than prior to treatment (20 versus 73 percent), median transfusion requirements were lower during treatment (2 versus 10 units), and median hemoglobin levels were higher during treatment (10 versus 7",
"    <span class=\"nowrap\">",
"     g/dL).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/54/41826?source=see_link\">",
"       \"Patient information: Angiodysplasia of the GI tract (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angiodysplasia can remain clinically silent or cause bleeding. Patients who bleed typically present with occult blood loss. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Angiodysplasia is usually diagnosed by endoscopy, but in some cases radiographic imaging or surgery may be required. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bleeding angiodysplasia require treatment, which can usually be accomplished endoscopically. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that angiodysplasia found incidentally during endoscopy not be treated (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Incidentally found lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treating nonbleeding angiodysplasia when found endoscopically in patients with iron deficiency anemia or evidence of gastrointestinal bleeding (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Nonbleeding angiodysplasias in patients with GI bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery and angiography are alternatives to endoscopic therapy and are typically employed in patients in whom endoscopic therapy has failed. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Angiography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H33\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternative therapies, such as angiogenesis inhibitors or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      , have also been tried, but data supporting their use is limited. These agents are generally reserved for patients who have failed to respond to more traditional therapies. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Angiogenesis inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H36\">",
"       'Octreotide'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/1\">",
"      Moore JD, Thompson NW, Appelman HD, Foley D. Arteriovenous malformations of the gastrointestinal tract. Arch Surg 1976; 111:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/2\">",
"      Duray PH, Marcal JM Jr, LiVolsi VA, et al. Small intestinal angiodysplasia in the elderly. J Clin Gastroenterol 1984; 6:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/3\">",
"      Schmit A, Van Gossum A. Proposal for an endoscopic classification of digestive angiodysplasias for therapeutic trials. The European Club of Enteroscopy. Gastrointest Endosc 1998; 48:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/4\">",
"      Yano T, Yamamoto H, Sunada K, et al. Endoscopic classification of vascular lesions of the small intestine (with videos). Gastrointest Endosc 2008; 67:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/5\">",
"      Gunnlaugsson O. Angiodysplasia of the stomach and duodenum. Gastrointest Endosc 1985; 31:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/6\">",
"      Clouse RE, Costigan DJ, Mills BA, Zuckerman GR. Angiodysplasia as a cause of upper gastrointestinal bleeding. Arch Intern Med 1985; 145:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/7\">",
"      Richter JM, Hedberg SE, Athanasoulis CA, Schapiro RH. Angiodysplasia. Clinical presentation and colonoscopic diagnosis. Dig Dis Sci 1984; 29:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/8\">",
"      Boley SJ, Sammartano R, Brandt LJ, Sprayregen S. Vascular ectasias of the colon. Surg Gynecol Obstet 1979; 149:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/9\">",
"      Jesudason SR, Devasia A, Mathen VI, et al. The pattern of angiodysplasia of the gastrointestinal tract in a tropical country. Surg Gynecol Obstet 1985; 161:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/10\">",
"      Foutch PG, Rex DK, Lieberman DA. Prevalence and natural history of colonic angiodysplasia among healthy asymptomatic people. Am J Gastroenterol 1995; 90:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/11\">",
"      Boley SJ, Sammartano R, Adams A, et al. On the nature and etiology of vascular ectasias of the colon. Degenerative lesions of aging. Gastroenterology 1977; 72:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/12\">",
"      Moret&oacute; M, Figa M, Ojembarrena E, Zaballa M. Vascular malformations of the stomach and duodenum: an endoscopic classification. Endoscopy 1986; 18:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/13\">",
"      Cappell MS. Spatial clustering of simultaneous nonhereditary gastrointestinal angiodysplasia. Small but significant correlation between nonhereditary colonic and upper gastrointestinal angiodysplasia. Dig Dis Sci 1992; 37:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/14\">",
"      Steger AC, Galland RB, Hemingway A, et al. Gastrointestinal haemorrhage from a second source in patients with colonic angiodysplasia. Br J Surg 1987; 74:726.",
"     </a>",
"    </li>",
"    <li>",
"     Porush JG, Faubert PF. Chronic renal failure. In: Renal Disease in the Aged, Porush JG, Faubert PF (Eds), Little Brown, Boston 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/16\">",
"      Zuckerman GR, Cornette GL, Clouse RE, Harter HR. Upper gastrointestinal bleeding in patients with chronic renal failure. Ann Intern Med 1985; 102:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/17\">",
"      Duray PH, Marcal JM Jr, LiVolsi VA, et al. Gastrointestinal angiodysplasia: a possible component of von Willebrand's disease. Hum Pathol 1984; 15:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/18\">",
"      Alhumood SA, Devine DV, Lawson L, et al. Idiopathic immune-mediated acquired von Willebrand's disease in a patient with angiodysplasia: demonstration of an unusual inhibitor causing a functional defect and rapid clearance of von Willebrand factor. Am J Hematol 1999; 60:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/19\">",
"      Heyde EC. Gastrointestinal bleeding in aortic stenosis (letter). N Engl J Med 1958; 259:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/20\">",
"      Imperiale TF, Ransohoff DF. Aortic stenosis, idiopathic gastrointestinal bleeding, and angiodysplasia: is there an association? A methodologic critique of the literature. Gastroenterology 1988; 95:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/21\">",
"      Shindler DM. Aortic stenosis and gastrointestinal bleeding. Arch Intern Med 2004; 164:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/22\">",
"      WILLIAMS RC Jr. Aortic stenosis and unexplained gastrointestinal bleeding. Arch Intern Med 1961; 108:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/23\">",
"      Pate GE, Mulligan A. An epidemiological study of Heyde's syndrome: an association between aortic stenosis and gastrointestinal bleeding. J Heart Valve Dis 2004; 13:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/24\">",
"      King RM, Pluth JR, Giuliani ER. The association of unexplained gastrointestinal bleeding with calcific aortic stenosis. Ann Thorac Surg 1987; 44:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/25\">",
"      Cappell MS, Lebwohl O. Cessation of recurrent bleeding from gastrointestinal angiodysplasias after aortic valve replacement. Ann Intern Med 1986; 105:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/26\">",
"      Scheffer SM, Leatherman LL. Resolution of Heyde's syndrome of aortic stenosis and gastrointestinal bleeding after aortic valve replacement. Ann Thorac Surg 1986; 42:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/27\">",
"      Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/28\">",
"      Bhutani MS, Gupta SC, Markert RJ, et al. A prospective controlled evaluation of endoscopic detection of angiodysplasia and its association with aortic valve disease. Gastrointest Endosc 1995; 42:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/29\">",
"      Oneglia C, Sabatini T, Rusconi C, et al. Prevalence of aortic valve stenosis in patients affected by gastrointestinal angiodysplasia. Eur J Med 1993; 2:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/30\">",
"      Batur P, Stewart WJ, Isaacson JH. Increased prevalence of aortic stenosis in patients with arteriovenous malformations of the gastrointestinal tract in Heyde syndrome. Arch Intern Med 2003; 163:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/31\">",
"      Boley SJ, DiBiase A, Brandt LJ, Sammartano RJ. Lower intestinal bleeding in the elderly. Am J Surg 1979; 137:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/32\">",
"      Weaver GA, Alpern HD, Davis JS, et al. Gastrointestinal angiodysplasia associated with aortic valve disease: part of a spectrum of angiodysplasia of the gut. Gastroenterology 1979; 77:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/33\">",
"      Junquera F, Saperas E, de Torres I, et al. Increased expression of angiogenic factors in human colonic angiodysplasia. Am J Gastroenterol 1999; 94:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/34\">",
"      Warkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link? Lancet 1992; 340:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/35\">",
"      Warkentin TE, Moore JC, Anand SS, et al. Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome. Transfus Med Rev 2003; 17:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/36\">",
"      Pareti FI, Lattuada A, Bressi C, et al. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation 2000; 102:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/37\">",
"      O'Brien JR, Etherington MD, Brant J, Watkins J. Decreased platelet function in aortic valve stenosis: high shear platelet activation then inactivation. Br Heart J 1995; 74:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/38\">",
"      Cappell MS, Gupta A. Changing epidemiology of gastrointestinal angiodysplasia with increasing recognition of clinically milder cases: angiodysplasia tend to produce mild chronic gastrointestinal bleeding in a study of 47 consecutive patients admitted from 1980-1989. Am J Gastroenterol 1992; 87:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/39\">",
"      H&ouml;chter W, Weingart J, K&uuml;hner W, et al. Angiodysplasia in the colon and rectum. Endoscopic morphology, localisation and frequency. Endoscopy 1985; 17:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/40\">",
"      Danesh BJ, Spiliadis C, Williams CB, Zambartas CM. Angiodysplasia--an uncommon cause of colonic bleeding: colonoscopic evaluation of 1,050 patients with rectal bleeding and anaemia. Int J Colorectal Dis 1987; 2:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/41\">",
"      Meyer CT, Troncale FJ, Galloway S, Sheahan DG. Arteriovenous malformations of the bowel: an analysis of 22 cases and a review of the literature. Medicine (Baltimore) 1981; 60:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/42\">",
"      Raju GS, Gerson L, Das A, et al. American Gastroenterological Association (AGA) Institute technical review on obscure gastrointestinal bleeding. Gastroenterology 2007; 133:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/43\">",
"      Marwick T, Kerlin P. Angiodysplasia of the upper gastrointestinal tract. Clinical spectrum in 41 cases. J Clin Gastroenterol 1986; 8:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/44\">",
"      Stamm B, Heer M, B&uuml;hler H, Ammann R. Mucosal biopsy of vascular ectasia (angiodysplasia) of the large bowel detected during routine colonoscopic examination. Histopathology 1985; 9:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/45\">",
"      Brandt LJ, Spinnell MK. Ability of naloxone to enhance the colonoscopic appearance of normal colon vasculature and colon vascular ectasias. Gastrointest Endosc 1999; 49:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/46\">",
"      Junquera F, Quiroga S, Saperas E, et al. Accuracy of helical computed tomographic angiography for the diagnosis of colonic angiodysplasia. Gastroenterology 2000; 119:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/47\">",
"      Rockey DC, Cello JP. Evaluation of the gastrointestinal tract in patients with iron-deficiency anemia. N Engl J Med 1993; 329:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/48\">",
"      Till SH, Grundman MJ. Prevalence of concomitant disease in patients with iron deficiency anaemia. BMJ 1997; 314:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/49\">",
"      Mudhar HS, Balsitis M. Colonic angiodysplasia and true diverticula: is there an association? Histopathology 2005; 46:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/50\">",
"      Sharma R, Gorbien MJ. Angiodysplasia and lower gastrointestinal tract bleeding in elderly patients. Arch Intern Med 1995; 155:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/51\">",
"      Wahab PJ, Mulder CJ, den Hartog G, Thies JE. Argon plasma coagulation in flexible gastrointestinal endoscopy: pilot experiences. Endoscopy 1997; 29:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/52\">",
"      Johanns W, Luis W, Janssen J, et al. Argon plasma coagulation (APC) in gastroenterology: experimental and clinical experiences. Eur J Gastroenterol Hepatol 1997; 9:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/53\">",
"      Kwan V, Bourke MJ, Williams SJ, et al. Argon plasma coagulation in the management of symptomatic gastrointestinal vascular lesions: experience in 100 consecutive patients with long-term follow-up. Am J Gastroenterol 2006; 101:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/54\">",
"      Vargo JJ. Clinical applications of the argon plasma coagulator. Gastrointest Endosc 2004; 59:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/55\">",
"      Norton ID, Wang L, Levine SA, et al. In vivo characterization of colonic thermal injury caused by argon plasma coagulation. Gastrointest Endosc 2002; 55:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/56\">",
"      Goulet CJ, Disario JA, Emerson L, et al. In vivo evaluation of argon plasma coagulation in a porcine model. Gastrointest Endosc 2007; 65:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/57\">",
"      Norton ID, Wang L, Levine SA, et al. Efficacy of colonic submucosal saline solution injection for the reduction of iatrogenic thermal injury. Gastrointest Endosc 2002; 56:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/58\">",
"      Suzuki N, Arebi N, Saunders BP. A novel method of treating colonic angiodysplasia. Gastrointest Endosc 2006; 64:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/59\">",
"      Ladas SD, Karamanolis G, Ben-Soussan E. Colonic gas explosion during therapeutic colonoscopy with electrocautery. World J Gastroenterol 2007; 13:5295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/60\">",
"      Askin MP, Lewis BS. Push enteroscopic cauterization: long-term follow-up of 83 patients with bleeding small intestinal angiodysplasia. Gastrointest Endosc 1996; 43:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/61\">",
"      Trudel JL, Fazio VW, Sivak MV. Colonoscopic diagnosis and treatment of arteriovenous malformations in chronic lower gastrointestinal bleeding. Clinical accuracy and efficacy. Dis Colon Rectum 1988; 31:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/62\">",
"      Moparty B, Raju GS. Role of hemoclips in a patient with cecal angiodysplasia at high risk of recurrent bleeding from antithrombotic therapy to maintain coronary stent patency: a case report. Gastrointest Endosc 2005; 62:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/63\">",
"      Pishvaian AC, Lewis JH. Use of endoclips to obliterate a colonic arteriovenous malformation before cauterization. Gastrointest Endosc 2006; 63:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/64\">",
"      Weilert F, Smith AC. Endoscopic band ligation of gastric angiodysplasia. N Z Med J 1998; 111:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/65\">",
"      Junquera F, Brullet E, Campo R, et al. Usefulness of endoscopic band ligation for bleeding small bowel vascular lesions. Gastrointest Endosc 2003; 58:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/66\">",
"      Bemvenuti GA, J&uuml;lich MM. Ethanolamine injection for sclerotherapy of angiodysplasia of the colon. Endoscopy 1998; 30:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/67\">",
"      Rutgeerts P, Van Gompel F, Geboes K, et al. Long term results of treatment of vascular malformations of the gastrointestinal tract by neodymium Yag laser photocoagulation. Gut 1985; 26:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/68\">",
"      Bown SG, Swain CP, Storey DW, et al. Endoscopic laser treatment of vascular anomalies of the upper gastrointestinal tract. Gut 1985; 26:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/69\">",
"      Naveau S, Aubert A, Poynard T, Chaput JC. Long-term results of treatment of vascular malformations of the gastrointestinal tract by neodymium YAG laser photocoagulation. Dig Dis Sci 1990; 35:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/70\">",
"      Hutcheon DF, Kabelin J, Bulkley GB, Smith GW. Effect of therapy on bleeding rates in gastrointestinal angiodysplasia. Am Surg 1987; 53:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/71\">",
"      Schmit A, Gay F, Adler M, et al. Diagnostic efficacy of push-enteroscopy and long-term follow-up of patients with small bowel angiodysplasias. Dig Dis Sci 1996; 41:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/72\">",
"      Olmos JA, Marcolongo M, Pogorelsky V, et al. Long-term outcome of argon plasma ablation therapy for bleeding in 100 consecutive patients with colonic angiodysplasia. Dis Colon Rectum 2006; 49:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/73\">",
"      Bell AJ, Mufti GJ, Oscier DG, et al. Angiodysplasia of the colon in patients with hemostatic defects: risk of secondary hemorrhage after electrocoagulation treatment. Angiology 1984; 35:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/74\">",
"      Uflacker R. Transcatheter embolization for treatment of acute lower gastrointestinal bleeding. Acta Radiol 1987; 28:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/75\">",
"      Barkin JS, Ross BS. Medical therapy for chronic gastrointestinal bleeding of obscure origin. Am J Gastroenterol 1998; 93:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/76\">",
"      Junquera F, Feu F, Papo M, et al. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology 2001; 121:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/77\">",
"      Lewis BS, Salomon P, Rivera-MacMurray S, et al. Does hormonal therapy have any benefit for bleeding angiodysplasia? J Clin Gastroenterol 1992; 15:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/78\">",
"      Bauditz J, Lochs H. Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol 2007; 13:5979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/79\">",
"      Ge ZZ, Chen HM, Gao YJ, et al. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology 2011; 141:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/80\">",
"      Mimidis K, Kaliontzidou M, Tzimas T, Papadopoulos V. Thalidomide for treatment of bleeding angiodysplasias during hemodialysis. Ren Fail 2008; 30:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/81\">",
"      Alberto SF, Felix J, de Deus J. Thalidomide for the treatment of severe intestinal bleeding. Endoscopy 2008; 40:788; author reply 789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/82\">",
"      Garrido A, Sayago M, L&oacute;pez J, et al. Thalidomide in refractory bleeding due to gastrointestinal angiodysplasias. Rev Esp Enferm Dig 2012; 104:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/83\">",
"      Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 2004; 62:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/84\">",
"      Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol 2003; 1:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/85\">",
"      Hamadani M, Benson DM Jr, Copelan EA. Thalidomide-induced fulminant hepatic failure. Mayo Clin Proc 2007; 82:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/86\">",
"      Andersen MR, Aaseby J. Somatostatin in the treatment of gastrointestinal bleeding caused by angiodysplasia. Scand J Gastroenterol 1996; 31:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/87\">",
"      Rossini FP, Arrigoni A, Pennazio M. Octreotide in the treatment of bleeding due to angiodysplasia of the small intestine. Am J Gastroenterol 1993; 88:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/88\">",
"      Nardone G, Rocco A, Balzano T, Budillon G. The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract. Aliment Pharmacol Ther 1999; 13:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/89\">",
"      Bowers M, McNulty O, Mayne E. Octreotide in the treatment of gastrointestinal bleeding caused by angiodysplasia in two patients with von Willebrand's disease. Br J Haematol 2000; 108:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/90\">",
"      Blich M, Fruchter O, Edelstein S, Edoute Y. Somatostatin therapy ameliorates chronic and refractory gastrointestinal bleeding caused by diffuse angiodysplasia in a patient on anticoagulation therapy. Scand J Gastroenterol 2003; 38:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/91\">",
"      Junquera F, Saperas E, Videla S, et al. Long-term efficacy of octreotide in the prevention of recurrent bleeding from gastrointestinal angiodysplasia. Am J Gastroenterol 2007; 102:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/92\">",
"      Brown C, Subramanian V, Wilcox CM, Peter S. Somatostatin analogues in the treatment of recurrent bleeding from gastrointestinal vascular malformations: an overview and systematic review of prospective observational studies. Dig Dis Sci 2010; 55:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/93\">",
"      Scaglione G, Pietrini L, Russo F, et al. Long-acting octreotide as rescue therapy in chronic bleeding from gastrointestinal angiodysplasia. Aliment Pharmacol Ther 2007; 26:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/13/8410/abstract/94\">",
"      Bon C, Aparicio T, Vincent M, et al. Long-acting somatostatin analogues decrease blood transfusion requirements in patients with refractory gastrointestinal bleeding associated with angiodysplasia. Aliment Pharmacol Ther 2012; 36:587.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2557 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-46D95CF9A3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_13_8410=[""].join("\n");
var outline_f8_13_8410=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Conditions associated with angiodysplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Venous obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Angiogenic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acquired von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Colon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Small intestine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Stomach and duodenum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Intraoperative enteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Incidentally found lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Nonbleeding angiodysplasias in patients with GI bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Occult bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Overt bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Endoscopic treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Argon plasma coagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Electrocoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Mechanical hemostasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Other therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Hormonal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Octreotide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2557\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2557|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/41/39583\" title=\"diagnostic image 1\">",
"      Angiodysplasia colon angio",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2557|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/13/20690\" title=\"figure 1\">",
"      Pathogenesis of angiodysplasias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2557|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/53/2905\" title=\"picture 1\">",
"      Angiodysplasia colon light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/41/3742\" title=\"picture 2A\">",
"      Angiodysplasia endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/37/21072\" title=\"picture 2B\">",
"      Colonic angiodysplasia Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2557|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/16/21771\" title=\"table 1\">",
"      Classification angiodysplasias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/9/14492\" title=\"table 2\">",
"      Endoscopic Rx LGIB",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24616?source=related_link\">",
"      Angiographic control of nonvariceal gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=related_link\">",
"      Argon plasma coagulation in the management of gastrointestinal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=related_link\">",
"      Classification and pathophysiology of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=related_link\">",
"      Clinical features and evaluation of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38679?source=related_link\">",
"      Colonic diverticular bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14101?source=related_link\">",
"      Complications of hemodialysis in the elderly patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7272?source=related_link\">",
"      Etiology of lower gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=related_link\">",
"      Evaluation of obscure gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11336?source=related_link\">",
"      Evaluation of occult gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=related_link\">",
"      Genetic and environmental causes of birth defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=related_link\">",
"      Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24649?source=related_link\">",
"      Overview of deep small bowel enteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/54/41826?source=related_link\">",
"      Patient information: Angiodysplasia of the GI tract (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=related_link\">",
"      Platelet dysfunction in uremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=related_link\">",
"      Treatment of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=related_link\">",
"      Uncommon causes of upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=related_link\">",
"      Wireless video capsule endoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_13_8411="Mitochondrial disorders";
var content_f8_13_8411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected mitochondrial disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Pyruvate carboxylase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phosphoenopyruvate carboxylase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyruvate dehydrogenase complex deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kearns-Sayre syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitochondrial encephalopathy lactic acidosis and stroke-like episodes (MELAS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myoclonic epilepsy, ragged red fiber disease (MERRF)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Freidrich ataxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pearson syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Succinate dehydrogenase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytochrome C oxidase (COX) deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitochondrial DNA depletion syndromes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_13_8411=[""].join("\n");
var outline_f8_13_8411=null;
var title_f8_13_8412="CKD Medicines PI";
var content_f8_13_8412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medicines for chronic kidney disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of medicine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generic name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sample US brand names",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Angiotensin-converting enzyme inhibitors (ACE inhibitors)",
"       </td>",
"       <td>",
"        Enalapril",
"       </td>",
"       <td>",
"        Vasotec",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lisinopril",
"       </td>",
"       <td>",
"        Zestril",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Angiotensin receptor blockers (ARBs)",
"       </td>",
"       <td>",
"        Losartan",
"       </td>",
"       <td>",
"        Cozaar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Candesartan",
"       </td>",
"       <td>",
"        Atacand",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valsartan",
"       </td>",
"       <td>",
"        Diovan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diuretics",
"       </td>",
"       <td>",
"        Furosemide",
"       </td>",
"       <td>",
"        Lasix",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other blood pressure medicines",
"       </td>",
"       <td>",
"        Calcium channel blockers (including diltiazem and verapamil)",
"       </td>",
"       <td>",
"        <p>",
"         Cardizem",
"        </p>",
"        Calan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Phosphate binders",
"       </td>",
"       <td>",
"        Calcium carbonate",
"       </td>",
"       <td>",
"        Many different brands and generics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium acetate",
"       </td>",
"       <td>",
"        PhosLo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sevelamer",
"       </td>",
"       <td>",
"        Renagel, Renvela",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lanthanum",
"       </td>",
"       <td>",
"        Fosrenol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin D",
"       </td>",
"       <td>",
"        Calcitriol",
"       </td>",
"       <td>",
"        Rocaltrol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Erythropoietin stimulating agents (ESAs) (These are given as shots, usually with dialysis)",
"       </td>",
"       <td>",
"        Erythropoietin",
"       </td>",
"       <td>",
"        Epogen, Procrit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Darbepoetin alfa",
"       </td>",
"       <td>",
"        Aranesp",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_13_8412=[""].join("\n");
var outline_f8_13_8412=null;
var title_f8_13_8413="SCOPER categorization system";
var content_f8_13_8413=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F85891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F85891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    SCOPER categorization system",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Sleep",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cardiovascular",
"       </td>",
"       <td class=\"subtitle1\">",
"        Oximetry",
"       </td>",
"       <td class=\"subtitle1\">",
"        Position",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effort",
"       </td>",
"       <td class=\"subtitle1\">",
"        Respiratory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S",
"        <sub>",
"         1",
"        </sub>",
"        - Sleep by 3 EEG channels* with EOG and chin EMG",
"       </td>",
"       <td>",
"        C",
"        <sub>",
"         1",
"        </sub>",
"        - More than 1 ECG lead - can derive events",
"       </td>",
"       <td>",
"        O",
"        <sub>",
"         1",
"        </sub>",
"        - Oximetry (finger or ear) with recommended sampling",
"       </td>",
"       <td>",
"        P",
"        <sub>",
"         1",
"        </sub>",
"        - Video or visual position measurement",
"       </td>",
"       <td>",
"        E",
"        <sub>",
"         1",
"        </sub>",
"        - 2 RIP belts",
"       </td>",
"       <td>",
"        R",
"        <sub>",
"         1",
"        </sub>",
"        - Nasal pressure and thermal device",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S",
"        <sub>",
"         2",
"        </sub>",
"        &nbsp;- Sleep by less than 3 EEG channels* with or without EOG or chin EMG",
"       </td>",
"       <td>",
"        C",
"        <sub>",
"         2",
"        </sub>",
"        - Peripheral arterial tonometry",
"       </td>",
"       <td>",
"        O",
"        <sub>",
"         1x",
"        </sub>",
"        - Oximetry (finger or ear) without recommended sampling (per Scoring Manual) or not described",
"       </td>",
"       <td>",
"        P",
"        <sub>",
"         2",
"        </sub>",
"        - Non-visual position measurement",
"       </td>",
"       <td>",
"        E",
"        <sub>",
"         2",
"        </sub>",
"        - 1 RIP belt",
"       </td>",
"       <td>",
"        R",
"        <sub>",
"         2",
"        </sub>",
"        - Nasal pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S",
"        <sub>",
"         3",
"        </sub>",
"        - Sleep surrogate: eg, actigraphy",
"       </td>",
"       <td>",
"        C",
"        <sub>",
"         3",
"        </sub>",
"        - Standard ECG measure (1 lead)",
"       </td>",
"       <td>",
"        O",
"        <sub>",
"         2",
"        </sub>",
"        - Oximetry with alternative site (eg, forehead)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        E",
"        <sub>",
"         3",
"        </sub>",
"        - Derived effort (eg, forehead versus pressure)",
"       </td>",
"       <td>",
"        R",
"        <sub>",
"         3",
"        </sub>",
"        - Thermal device",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S",
"        <sub>",
"         4",
"        </sub>",
"        - Other sleep measure",
"       </td>",
"       <td>",
"        C",
"        <sub>",
"         4",
"        </sub>",
"        - Derived pulse (typically from oximetry)",
"       </td>",
"       <td>",
"        O",
"        <sub>",
"         3",
"        </sub>",
"        - Other oximetry",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        E",
"        <sub>",
"         4",
"        </sub>",
"        - Other effort measure (including piezo belts)",
"       </td>",
"       <td>",
"        R",
"        <sub>",
"         4",
"        </sub>",
"        - End-Tidal CO",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        C",
"        <sub>",
"         5",
"        </sub>",
"        - Other cardiac measure",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        R",
"        <sub>",
"         5",
"        </sub>",
"        - Other respiratory measure",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Proper oximetry sampling is defined as 3 s averaging and a minimum of 10 Hz sampling rate (25 Hz desirable)",
"    <sup>",
"     [1]",
"    </sup>",
"    .",
"    <div class=\"footnotes\">",
"     EEG: electroencephalography; EOG: electrooculography; EMG: electromyography; ECG: electrocardiography; RIP: respiratory inductance plethysmography.",
"     <br>",
"      * 3 EEG channels defined as frontal, central, and occipital.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Iber C, Ancoli-Israel S, Chesson A, Quan SF. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications, 1st ed. American Academy of Sleep Medicine, Westchester, IL 2007.",
"      </li>",
"     </ol>",
"     Reproduced with permission from: Collop NA, Tracy SL, Kapur V, et al. Obstructive sleep apnea devices for out-of-center (OOC) testing: technology evaluation. J Clin Sleep Med 2011; 7:531. Copyright &copy; 2011 American Academy of Sleep Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_13_8413=[""].join("\n");
var outline_f8_13_8413=null;
var title_f8_13_8414="Graded benefit of fitness";
var content_f8_13_8414=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Graded survival benefit of physical fitness",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 262px; background-image: url(data:image/gif;base64,R0lGODlhrgEGAfcAAP///wAAADMzMwAz/6qqqhEREYiIiHd3dwBmM/8AAO7u7qCz/1VVVczMzP/w8P8wMP/Q0GZmZiIiIv8QEEREREBAQICAgBBA/8DAwN3d3bu7u/Dz/5mZmf+AgBBwQP9AQDBZ/4i4oIig/0CMZtDZ//+IiPD28//AwGCA/6DGs9Dj2YCZ/0Bm//9gYHCpjTCDWeDs5mCggCB5Tf+goMDN//+QkPDw8MDZzf9wcJC8pv8RERAQEDAwMICzmbDQwBFB///g4ODm/1CWc/8gIHBwcP+wsBFwQaCgoLCwsFBz/3CN/+Dg4NDQ0HeS/1WZd/93d7DA/5Cm/5CQkCBN/1V3/2BgYP9VVXetku718f9QUP/u7u7x/2ajhUSPaf8iIiJ6Tqq7/zOFXKrMuyJO/1BQUP8zM0Rp//+qqjNc/5mt/yAgIP9ERMzg1szW/2aF/5nCrd3r5P+Zmf/d3f9mZv/MzN3k/wBZZqC82WCMzGCZmTBmzICmzABMmVCDvwBiP+Dp84Cj2ZCzzNDW00Bp8v+7uzBzmbDG5sDT5kBzzBBZmRBF5VCJprvJ/zBc8rvWyQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACuAQYBAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePPq3cu3r9+/gAMLHky4sGGOFAI0EKggcQAKGQ5LnpyQQIDLiwEwCECgQQABlEOLFrg5c4EACgCcTj26tcwSCUpELQ1AQYACAle73t2whI4ECdbIoQj7CQAtCXQAgC17oRYvyoPSVo2aOuuBl7Nf5t0athUAdHR4/9EysXhB5gufAI8OdPpmAho+MwzAfbSXBMMBzEkQ50yC71bEBsBvwH2nnhU6rAEccFrooBx6cdz330EOAmVZdgzU5hhk89VXGBAFIcdecf4BKOBA9xGiHnBPmDfgg7HRkUAZ+vFnUIVY0eehYCckACJB9+W3X38TBijbisCdoV5zLlbIHGwLJmBcQThepeOOf0EwwQwGeQeeeFr4R6ORsK0BQIBKngjbHAI5GeOMClVp1ZVY8qUllwf5BpxwAinoRRmxaQGoDoCm2ZygDLopW4QLNicQkidWRWedeQExQQ0LoceVBpEBwGlJk1JqlwMPtMCQFgpGipUABwh0AGgkhf8q6lykmqqWBgIUIIEAucI6kqyzxvVAFmxdmF0BHIAarF0tPOBAWwpEYIAC18W6LF3NPuuWAgYc4K0Byl4bV7ZwOXaZryIBKy5aM0wAAVy2CUDAvBqEuy5b7b4bF6spqXvvWPnOFYEE3h4ArrX/pgVBAkXQJYB26Ibkb8Je3VmXBgbMO2+62VFslsV1GXAZAQJEYK/HYTkwBA537SoBAa+ejLJXtd5lG8kERBAxSBPPXFXNeEmg8wEFmIywz1198IFeHBzb6a9Id0WuXhoY/DTUUWs1dV4HUABAAwIke3TWVuEwhLY6iTCACD0VcDADO3/UM9lLBayRCD8MMIAZdVD/pHYTAGwxwA8AqM22QmrrTQVLN7sat0dz042U3RmpvXgbP4yxxUR/F2T4Qk2AAUATa7PEKwccFC2z5E4VkYC+Go0xQN8AuDFAGmAMsDgVpeet+Oi6/2CG3npv8QPhn6chu+4I2Q74Sk1fVsDVErMeFcgUBVGQ4IQL9Hfuu5c+kOyMkK53E50DcHzha7cxABq1325Q4m201IDVJkVufVDYT7TAANojiOxoZzvcMY93bDOf3sBAusOlb32GSxzxnieQLQxPfCuJgNFOor/9+aR/ElnABaAwP+ZhTnO5gx8C1WYGAPCOgeJTmxsEAsH2vQ8heftBGlwCt4s0wDEv65AH/5UCNIqIkAQIwZve+CaQ4Y0BDWvbAhR/AEUYHk6Kxash25RHvMPRkHiDY4kBClCwg0VEAorJwG2EOMSjFHEiUbgAEhGHQa08LDuPW8hmKCCyDSakg228yRslggI5MsSCevMiVjSgMfhMxDOXkYDYFALIQNYkCw+wCApAMEe2ZIAACgDlRCSAGwKchnra6Zglh7I1QoJgA24RGWdKNpECTA8AaKSeQSq5Spi0MiKbhKVbXAazPCqEZOciABt72ZMaTOBHEtkACF75lpvJS2erYyZOKBcRabJAmG8RGqtUNzZtbtNdFJEmCuYSvdvoUm7m1EkHEnCCdIJgnXSpmgHeCf/PeNoEAg94QD0nQoIL4JMuHMBfNv3pknl2oCIFVYJdInCszGCNoTAB6ANgJ5GCLsAutmEAAVLntXJidCUOtYhH8SIvxy30pCXRKEdDeIGP4iUCFPAWBXJqRp7BFKUJeKhF/mdTlqZSPun6KUpkepEj7oWRjXRkUpVakpQ21ZAz4yVVIcLUiygBq1ndakisepFCdjKsYu1IV8tKzahpNa0IIStbwQkYAoiUY9uBK0bWapENJKGtgonPYyzqU71aRK59nSZd/fK0UBrsooaNCF8Ti4LF+kUAfETJW+GKWMoWhqK3YUC9TBpZhUxWpfc8TAbGeK5JFra0DOmsSg16GA3/DCySSK0ebE0b0JlepKBRkMzDhLaYBvS0n7s9iGxnW1TDGMC1Ly3taS9Cg5pS5lOe4mdHNsvQ5Q51AM09DL8AEDPSRna6TQXvdXO1q15FN601COpHiBoaY0kPuq8trQM+sNH5qlc00ZpWtSBr2CJMAAdo4wh9RXOA1RbssRPhwB1btRDuBtIBOJhAw/wbXslYE2ITsUyGHGLhIQL0AwlW8H9HA0qo0msiiUEjspYp1vhiCiQLjtpqMmBLGit1v/3F8YqhEgIEhGAnDy7jKAMQmYcRFgBHLbHkDIzgkOT4JSEwAgIQ0AU4UKTIVwAAFhBgBAAU+cgK4cKWEeAELKTE/zZHNWZCDhCAferKxxjFsIZFcmWXFNkJAGCDEb7gZomAuSBnXkgX2AAANaMZJVF98UQ2M1g8+/PEKe5In13yBQR4udEIeIMY2AwAJxgZAFreMqCvwGYjdGHNCMCCEcqc6Dd0mtQHUbMYxHiac723lzYeyaZbMuYyCwTMowa0qR8NgE47gtVbvsKhUU1rI7MBAWEA9RsQveVss0QCaMzViAkcTyD7VtNDPokJUiAEBBik059Ws6hJvWwAQHvLYmA1mqc9azMbuciwDrNBisyFldhGZNEa91QZSuVMo7vDI1l3u0eQAhMMnNSCJvSos73sIneh1AjI96n9XXBq+zsE1//2dkHY0GWSG3yWB+iheS2p5w3zOd0j8UEMEPCCHMBAIVnecssB8OovhMHIWDi6EY4ucjQnfcuyrvaRbb3mR2Ph1aoutEoEwAA6B8CPujUnpkky7I/o3AM9/7lDEv0VAxw37MwMNtlx7pGzy8DnErn6lpl9Fexil9xtNHdJyq4RFbjAAzJwgQrqMt7yAt6DDR883TNieBkkfvEXYy+vCiBnjUh5WTU3CeErUnkPKD4v9r0NfpFr4gegWPSTpwgMciADD8TAB30JMLU4GEi5Sx7iE5n9C2yPe8BosF9DFDzsgQ8R4SPg9oSROe/3F/nlW2TdI0CAECruXDJ+69cUC/3/SUa/EHZrn/vCBfHMUTb28cdeIWfvucVD42Kp8kyVZJtBAm7sfuYjpPKJp3auYX/rlzDONFD99xDCZ3uYtxsN0GsCMGD55TMtgE4oQX4CIXHaV3z1AW4HEAEFoHBwhzIO8Etz538CoXM8h34e0jjk1XkZ8XmjQSrOkhKjZ3iIh3eiIgEiJWEiOIEJAwSlohJlN3u1d3rLIku38WRAeC9aYisXiHPr9gLPx4Hiok/atV0ocwJbQoTp5gPttn3zdy8EQAG8QksFKCr6hydRWFQqEANop4MU02u+loZ10gEW2IYAAAMuYHlIODNFQy0S2ITB0gJDcG7CdgGAkAPDB31Z/2MAFKAxo/V4lOIAmORwiRgI58c6oFWHlIglpPJ6KRFHd+ABKWA98aJkdsgbAAWFKFFIpXiK+0MBYEcRgqVMFXYtWsIyKrFJhuABOTBEDMB5vFKLDpEBpMQZluYhBsaGrwgCf/ACMdBGd+SJEcF177GM3NEuzngSmxSN0xhIgjiIDWGGmqGMuSgqGYaIIiFNr/QCQrBbkKQduIgdRyUqzcKOIeFNGxADLzCGyZWN6bgjQIaJ7Zha/giQAYmOlASKw2KQ+4iQ/8hMnxRK5KiFHgIBQ+CKJ1FQ65QCHtCAliRLJGOMkJOREyBUKRFRAACSImlJxOR4C7cb3LgSK+WS2v9kTTkDgxghg3bRLjaHEiulAghghb0kTkRjkhjpGhWoj1ZmXSpgiv7UTre0ioLRLNCkh1Epi/6EhfnTGjQIkU+JRCaQeBiVhYRYGLUiljhmSCYgjSfFK/s0fZTxhCzxVWQJlyfViXdllXZyKSxhVgIxAiMQGCLzdjiRARKWWzOpljiQAN3ojW2VkG3XaxwyESLTKraBG4fZELJ0kSNhW2gUAD/IeoThTB/glCERTAJBmV4hMhnygBIAmgmRmQXRmQthGbqxEsMVAZP4iXxxAkMwBAiYEn7VVn2okFuRSwJBURwgYucILnSYIXQ2jOaCGj3WmRwwmiLIY6xFmyHxXMj/NxhA8AGAyRLuKEw4mRU2UBCbORCZCZ2b0VNoVDXZYTABQGHZWWeeARrOORAKIDTWoRIN1i2qCJx3gWEJUGXoeU/qGZJaIQUB0J4EwZwA4JzyWWfkRY90djC2qRqcWWdKeBkUBgAjehngyREfhkd45ZNkgZpZqRLqNBA+gAAvSRU2UAE8wAQGAZtfoyuhJB/zKTJe8x4dKhB9lBshagD9uRC7CWkKUH+/OYJ6IZzE+RIkkFoCsZVZgQQ7QAQU2qOW2Skx9jDT8jCcxxlHWht3pAD7CS7bmR2I+aQp4Xdo6Xl9UZ7n6RIeORBcehU2QAQ7gAQMgZtb0Xg8eREu2hUK/8qgfHoBwbWlUnkVTMADFRCmCtEYl4GYUoErurJ5iWoRi7oVMBoTK5WBemkVEioFbZF6M+aXaGGlxekS1VVUbxmOVZGjO1pN0rJ7X1kXesp/HUkDNLACxsoCyKo3tpqqVOGlYDoXgvirctGobDkRQUCsC2CsSYCsF6A3U4CsSmCsUECsGxBAAiEEL2AVgTqoc8Fa1kilbVGqE7EBG0CsUGCsSoCsU6A3F4CsSWCsC0Cs5toQrjkVlXqpdAFunxGC4EcWsloRK6A3yMoCxroCxHpWF1GwUrGqdXFwqBEBpXmSbhGsFREE04SxH5EDHiCAUaGrPNqxMCd9jYkW1FoRcf+0AiWxnlLhrJjqMF13GUrJEaPKFPJqrSwwBTSQsxAqFetKqHzhdtJ6Fg9bEVBwAUpgWR0xe+12AwZrqT1LF0n2fRLxgJdxmQ15FiRbEX51AUkbEirAiOd3o03BsXkBZ6kUqvAJLpZRUmdbFvHlqBNRtUmAtZTXh8SXqzr6snoRaQQoEU3TeUNLFCV4iH1VSCRUdzHgh0a5s1/6tXlhoGIbYqfBqQQRuULRfhRBA1MwuByxbnD4An+Yq4LqtH9RjYwJEaBVmlEGMCnZV18VqRmhgWmnFQfruU+lMW4zaSRKYmKRYUHZUSDAAgNbEc63fSyLFXRrGJilvNrBhAVhuj3/QYMxGhERC7yk5wKNyIJa4bKFYaAUhbcUAb47wYUcGRFZykkWcQOG64hewbPaqx2rJ7JcgYeRCRFRMAA4SxF2F7td0bSS4WLea5pXYYlBZrT4GxEwYH49J7dcUbyBJL//NARZUK0IEUdXGxEm4AIIMAJy2BUYgAQWQAQVoAYBwKqUUYZnGLQbAcI0oX/C2k1JgLQSobIjcL3q+sIWUAUVsAMBYKlEYAEYwATGSxh0eLtp+RQlOAGzChFVW1kRcQOWx7W5igFHYAFkUAGXYakWIAUYsAQeEoi+CqtGIYSiGE1JMEIYPALAGBVLgAFSYAE6ehkVQAYWcAQYMMXcAYmS/9iwSEFlFVFdrPsQKYwALqCcRcEEGBDDgbwDFVAFFoAEh5wwnWjFEvwUzptOX3W5D0HERnwTGPDKZGwBsizDFVDLTBwAalABTwzKUZOKoTuzTQFk4+sQqiu9EAHGMiDGK9HHsCzLsnzGtcwD2mGptUzIzgzLbTxEtDieUEG/JGwQKwCpzafHwXgQGFAFUZbO6rzO2cHJtazLzmzIsLxVw5jDjCwU8VXADXG/06sQk1zJB3EEPLADFuDGyXUStgu/E8HDKGGJlCsRUJAECAwRrGwQS2ABO8ADR3DQBhet9/xBD2m/hQQCUdDPCYHMyjwQ5xwAVYABHL0SoAthCBoU7f+ikg0RBFEwBVaLsgoBA+RsEAJN0Ab90lunfjP9ExW4xQmxABKdBKrsEP8MkBed0RtN1C3hYskrMfh3FEJYgwxBAyO9AISrEBWt0ujc0lY9E9srxzfhyAsRBCswBVOgBCbNEChNEEFd0GkNE+5LygJcFASsEBuwACwwACjw1OO8xwIx1Rq91zJhuwG8lEOhfAcBBYXEAmJNEVEtECuN1o4tExActfyzkQ4XBEog1ytQ1w5R1nk91J/9EiQjNhJWj8BsEw5wAifQAR2gNBOwfwYx2CBgUG1bEXfN2FX92jIxjATBsGwtErhdAx2QBR8wBMChNDjQATNwAkCQYpY9AEn/kNkW4dN73Nkujdw0wSsEgd7NvVcnMAMd0AL8BRyu1wIdUAMnoJok8FVTUNIQoQI3cAM9EOCEmX2UbAKtbd42kSus4aYKLRGmCwQnUAQdgANKAxxD8AFZoNu4HU1RENwowNMw8N8pEOBCQJgesGUyQJguEOA+8N8mIAgY3dgIfhMiQzAHgEakK7QScdu4fQLQrdsUrjTmCRwToDS6XQQn8M0AQALEWrETqzeDgAc34AMB7gKEKQNb5gGEKQQBngL/rXaYnMmy/M6X4dkzjhOjzLdHLRALIuQfQN+63QE9rt0Oca00kK0rsK0s0K0D8K2NoAeIwAeFYAd24AdbNuAB/94D/415zFzGZmzLl5HL8PzJr4zIZz4TVXMAkf3XH1GvNHCvK5CvR8uv/mqseLAHi5AHJY7lKzwCK+7lP2cDrwzDmjzDl+HO1izPrn3pb+GiQbAASgACEousFUusd3ADIx4DI0CFPDcCMdADOXADiyfrYg7pAfDO1xzFvO4XUlasd3wB/5q0IU7lVk7gKc7lii7Gr/zHZ0zD1w7Phrzr2x4XmvoYd/pWvx7sA6AIetAHedADJo4AWj4CLH4DFofJZazE0tzEnbzG2j7vffEeTTqQDnEIe9AHicAHhG7oA1/wP9fHMEzLkT7IsvzKEG8YukGnB9FB7JzO7izLoGzpJ/8fGO85oH0784GU8tVRui3f8z7/80Af9EI/9ERf9EZ/9Eif9EqfV4DxHvEBubWNp/C6w1Efg2u+0IJR72b7R1Xfk12vqF8vqlfv4B4SuWYf9hVx9lNP9WsfGmp/xV7f9nEP93NfyqPx9nYv9XQv9nJf95zuGnj/9zre93y/94Wf9zif+Iq/+Izf+I7/+JCPUamzqUORGA3eEkoYsjeRGJlBtvbOE5w/EIuZn6HRpAL5E0Tj1zjRNBlCUTkuE8aSGVC7tzoR+wIBnaNhmx/qE6nzuEDhGWQ0jHea3IpREL6/E9MRY6oXGke6+zwRHxww8T9BaaSZojExHbc/ujwxHTv/1mOUofuk7xPU/6460ZmJocMzgf252xPTwZxORhlNmhi07RPS3xNJmqTsX/znGP7bDxABGgAAcCCAgQwFJBBk2NDhQ4gRJU6kWNHiRYwZHXIoEOCgRpAhLTYIIEDkSZQEI3gMECHly4sEWAZgAIDBTIEwdT6UybKmTY8UBu4kWtToUaRJlS5l2tTpU6hRpU6lWtXqVaxZtW7l2tXrV7BhxY4lW9bsWbRp1a5l29btW7hx5c6lW9fuXaoNJNBsyMGjgYcka94citfwYcRKNQQooACoS6UUcjZUGFEw0MKJNW/mDHIlg8USHCsVEGA0QQUlLfMl3Nn1a9gOFeztyAGA/4KbASQQABo0Q+oCkhUY9PiTYIPSAShkyB2AN8GOHhVwLA7gcmviHztmWEwBgOTnDEs3IFkAQOnk4WOvZ3/Vr3KCNwlk0N3wpoHULGWafCih8WKTOjrNOtVIMsmAAA64TiAED/jOuZs4iKCAAuhrjCWTxivvPIESMq89EEOMaq+homNJAQP28ugA4FCT7C+GDLxNOgEbkrFBAPZbsAH5CkpQpggkWGnIhzRkjMOBahRxSSaPGi++AGw77sgGW2xIpoUY8k8BAAFQckqTbkxwRxzB83I7/wLQoEjnNhwvtCbjlPOlJ29rzrzcSmPxSAAQ9EgA9ZDzzUvTbFQNAOpaInVwsJyIKwAwAFZaSFKIepLMvNI6kiCzOTv1tNM6PxV11CZDJfVUVFNVdVVWW3X1VVhjlXVWWmu19VZcc9V1V1579fVXYIMVdlhiizX2WGSTVXZZZpt19lloo5V2WmqrtfZabLPVdltuu/X2W3DDFXdccstVNiAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative age-adjusted mortality from cardiovascular causes over 16 years of follow-up, according to fitness quartile in healthy, middle-aged, Norwegian men. Mortality varied inversely with fitness (estimated from total work performed on a bicycle ergometer), being lowest in those who were most fit (Quartile 4).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Sandvik L, Erikssen J, Thaulow E, et al. N Engl J Med 1993; 328:533.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_13_8414=[""].join("\n");
var outline_f8_13_8414=null;
var title_f8_13_8415="Algorithm for management of rotator cuff tendinopathy";
var content_f8_13_8415=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Management algorithm for rotator cuff tendinopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 706px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_13_8415=[""].join("\n");
var outline_f8_13_8415=null;
